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Abstract
Parkinson disease (PO) is the most prevalent human neurodegenerative movement
disorder. Hereditary and sporadic forms of PO share pathological features including
oxidative stress, protein aggregation and mitochondrial dysfunction. PINK] (PTEN
induced putative kinase ]) encodes a serine-threonine kinase linked to autosomal
recessive and sporadic PD. With no animal models available at the commencement of
this thesis, it was our goal to study the gene within a Drosophila model of the disease.
We identified a Drosophila melanogaster homologue of PINK], and used transgenics to
employ expression studies along with morphological, longevity and behavioural assays.
We have found that Pink] is able to improve the effects of toxic proteins, including
overcoming the effects of a-synuclein and Gal4 overexpression. Our results suggest that
increases in a-synuclein and Pink] together can have a synergistic effect, allowing for
enhanced protection and increased functional longevity. Additionally, our studies have
identified the possibility ofa non-protective role for the Pinkl/parkin pathway. We have
found that an increase in Pink] or parkin is able to increase the damaging effects of the
directed over-expression of Foxo in Drosophila, highlighting a possible role in the
apoptotic pathway. Taken together, our research highlights the complex role ofPink],
where it likely functions in a Pinkl/parkin pathway to operate in the ubiquitin-
proteasomal system, regulate mitochondrial fission/fusion events, regulate membrane
permeability during apoptosis, and other roles that may be independent of its kinase
function. Further investigation into the Pinkl mechanism of action will be important for
the future development of disease modifying therapies for Parkinson disease.
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Chapter 1
Introduction and Overview
1. Parkinson Disease
Parkinson disease (PO) is the most prevalent human neurodegenerative movement
disorder (Lees et al. 2009; Weintraub et al. 2008). As PO affects I to 2% of the
population over the age of 65 years, age is considered the largest risk factor for the
development and progression of Parkinson disease. PO is characterized by a progressive
loss of dopaminergic (OA) neurons in the substantia nigra pars compacta, resulting in
age-dependent increases in bradykinesia, muscular rigidity, gait abnormalities, resting
tremor and non-motor symptoms including autonomic and cognitive disturbances.
Currently there are no cures and few disease-modifying therapies for PD. Dopamine
replacement via levodopa can temporarily improve motor symptoms, however, non-motor
symptoms are largely unaffected and further motor complications can develop in patients
(Poewe et al. 2010). Investigation into the underlying mechanisms of PO may provide
the means to develop disease-modifying therapies.
Although sporadic forms of PO are believed to be more common, 5 to 15% of PO cases
are of an inherited nature and share features with sporadic PO, including oxidative stress,
protein aggregation and mitochondrial dysfunction (Dawson and Dawson 2003).
Commonly favoured mechanisms in both forms ofthe disease include abnormal protein
degradation, mitochondrial dysfunction, calcium imbalance, and inflammation (Gupta et
al. 2008). It is generally believed that a combination of environmental factors and genetic
susceptibility playa role in the development ofthe symptoms associated with PD. With
the precise pathologic mechanisms of PO still unclear, the use of familial forms to
understand the genetic component may help us to understand sporadic forms of the
disease.
The discovery of inherited forms of Parkinson disease has renewed excitement and focus
in PD research, and has led to the emergence of an increasingly complex network of
genes found to contribute to disease risk and progression. Currently, mutant forms of at
least six genes are linked to familial forms of PD, including o.-synuc/ein, LRRK2, uchLJ,
DJ-i, parkin, and PiNKi (Gasser 2007). These genes highlight key cellular systems in
the pathogenesis of PD, including proteasomal protein degradation, reduction of oxidative
stress, and maintenance of mitochondrial function. Mutations in other genes, such as the
mitochondrial protease OMVHTRA2, are also involved in hereditary forms of the disease,
where they can considerably increase the risk of developing PD (Meissner et al. 20 II).
While the identification of PD genes may potentially provide insight into the disease
mechanisms, at present we do not fully understand their biological functions within the
cell. Investigations into the various, and often multiple, functions of the associated
proteins and identification of their molecular targets will be necessary for designing
effectivetreatrnents in the future.
2. PINKl/parkin pathway
2.1 parkin
The parkin gene is associated with an autosomal recessive form of Parkinson disease,
with an early onset typically between childhood and age 40 years (Lucking et at. 2000).
Functioning as an E3 ubiquitin ligase, parkin interacts with ubiquitin-conjugating
enzymes to catalyze attachment of ubiquitin to protein targets, tagging these proteins for
destruction by the proteosome (Bekris et al. 20 10). Many ubiquitination substrates have
been proposed for parkin. One such substrate is the u-synuclein protein, a major
component of ubiquitin-rich inclusions known as Lewy bodies, often present in the
remaining neurons of PO patients (Lees et al. 2009). The a-synuc/ein gene has been
identified as central to the pathogenic mechanism of Parkinson disease, with links to
oxidative stress and various aspects of mitochondrial dysfunction (Oevi et al. 2008; Liu et
al. 2009; Schapira and Gegg 2011). It has been suggested that u-synuclein aggregation
through Lewy body formation is a neuronal detoxification response (Whitworth 20 II).
The presence of ubiquitin in these inclusions suggests that parkin not only tags u-
synuclein for degradation, but that it may be involved in this protective, aggregation
response.
Parkin is predominantly a cytosolic protein that can co-localize to synaptic vesicles, the
Golgi complex, endoplasmic reticulum, and the mitochondrial outer membrane (Bekris et
al. 2010). PO-linked mutations in parkin can result in the alteration ofthis localization,
as well as modification of its solubility, aggregation and function. Orosophilaparkin
mutants exhibit motor deficits, associated with dramatic, widespread apoptotic
degeneration of muscle tissue and male sterility (Whitworth 20 11). This phenotype
appears to be the result of a severe loss of mitochondrial integrity, suggesting a role for
parkin in mitochondrial homeostasis (Greene et al. 2003). Mitochondrial defects are a
common characteristic of sporadic PO and are associated with parkin mutations in
humans, and in animal models of PO (Whitworth 2011). It is possible that parkin acts to
regulate mitochondrial integrity and that mitochondrial dysfunction is the main
contributor to the loss of dopaminergic neurons in patients with parkin mutations.
2.2 PINKl
PINK1 (PTEN induced putative kinase 1) encodes a serine-threonine kinase that has been
linked to autosomal recessive and some sporadic forms of Parkinson disease (Jendrach et
al. 2009; Valente et al. 2004a; Valente et al. 2004b). Identified as a kinase, PINKI
contains a mitochondrial targeting sequence and has been shown to locate to the
mitochondria (Silvestri et al. 2005; Valente et al. 2004a). Initial studies into the function
of Pink 1 in Drosophila have shown degeneration of indirect flight muscles and defective
spermatid formation as a result of null mutations in Pink1 (Clark et al. 2006; Park et al.
2006). The phenotypes are accompanied by mitochondrial defects, with one study
showing mitochondrial swelling in the dopaminergic neurons of Pink1 mutants (Park et
al. 2006). These results, as well as others using an RNAi approach to target Pink1 (Yang
et al. 2006), suggest that the pathogenic mechanisms responsible involve mitochondrial
dysfunction. Further support for this theory can be seen in cell culture studies reporting
that PINK1 mutants are unable to inhibit cytochrome c release under stress conditions
(Wang et al. 2007), and that overexpression ofPINK1 results in a reduction of
cytochrome c release from mitochondria under both basal and stress conditions (Petit et
al. 2005). In particular, PINK1 appears to be important in preventing oxidative damage,
where mutations result in oxidative stress and a decrease in complex I activity (Hoepken
et al. 2007). Complex I dysfunction is a common feature of sporadic PD and is thought to
be the result of increased oxidative stress that causes an abnormally high rate of mutation
accumulation within the mitochondrial genome (Schapira 2008). PfNKl may confer
protection of the mitochondria through several mechanisms including an interaction with
molecular chaperones to regulate oxidative stress responses, activation of parkin to result
in the tagging oftoxic proteins, such as a-synuclein, for degradation, or through the
interaction with proteins to preserve mitochondrial integrity (Deas et al. 2009). In
addition to maintaining and stabilizing mitochondrial networks, it is becoming
increasingly apparent that protection during cell stress is due to the involvement of
PfNKI in mitochondrial fission/fusion events (Chu 2010; Jendrach et al. 2009). This
involvement implicates PfNKI as a key regulator of the fission/fusion balance, using the
process ofmitophagy to specifically process and degrade dysfunctional mitochondrial
fragments.
2.3 PINKlIparkin pathway
It has been suggested that PfNKI and parkin function in the same pathway and that this
PfNKIIparkin pathway is necessary for proper mitochondrial function and morphology.
This is supported by the striking similarity between Pink] and parkin mutant phenotypes
in Drosophila (Clark et al. 2006; Park et al. 2006; Yang et al. 2006), and mammalian
systems (Dagda et al. 2009; Exner et al. 2007). Studies show that overexpression of
either Drosophila or human parkin is able to rescue Pink] mutant phenotypes, but that
Pink] overexpression does not influence parkin mutant phenotypes, suggesting that Pink)
operates upstream of parkin (Clark et al. 2006; Park et al. 2006; Yang et al. 2006). As a
kinase, Pink) may interact with parkin through a phosphorylation event, and although
there is some evidence to support this in Drosophila (Kim et al. 2008), it has not been
supported in mammalian studies (Vives-Bauza et al. 20 I0). It is possible that PINK1 may
provide protection through an interaction with parkin to result in the tagging of cystolic
proteins for degradation, as neurodegenerative diseases are often characterized by the
accumulation of toxic proteins. This role is supported by the ability of Pink I to protect
neurons from the dopaminergic neurotoxin MPTP (Haque et al. 2008), where the
pathology of MPTP is attributed to the a-synuclein protein (Dauer et al. 2002; Klivenyi et
al. 2006). The expression ofparkin has been shown to rescue an a-synuclein-induced
phenotype, presumably through the targeting of a-synuclein for degradation (Haywood
and Staveley 2004, 2006). It is possible that the ability of Pink! to protect against MPTP
is due to an interaction with parkin that results in the targeting oftoxic a-synuclein for
degradation.
Increasing evidence points towards the importance of the PINKI/parkin pathway in
maintaining mitochondrial function in the cell, segregating damaged or dysfunctional
mitochondrial fragments and promoting their degradation by autophagy (Whitworth and
Pallanck 2009). In this way, the PINKI/parkin pathway acts as a quality control
mechanism to degrade damaged mitochondria so to prevent their dysfunction, increased
ROS production and potential release of pro-apoptotic factors. Recruitment of parkin to
the mitochondria, under various conditions, appears to be dependent on PINKI
(Whitworth and Pallanck 2009). Once at the mitochondria, parkin can initiate mitophagy
through the ubiquitination of mitochondrial membrane proteins. Two proteins identified
as targets for ubiquitination by parkin, VDACI (Geisler et al. 2010) and Drosophila
mitofusin (Poole et al. 2008; Ziviani et al. 2010), have been recently reported.
Ubiquitination ofVDACI likely results in the recruitment of autophagic machinery,
while the ubiquitination of mitofusin may directly alter its function in mitochondrial
fusion. Although there is growing evidence for a role ofthe PrNKl/parkin pathway in
mitophagy, there are indications that they are not obligatory components, but instead
regulate mitochondrial fission/fusion only in a specific biological context (Whitworth and
Pallanck 2009). Future studies into the conditions required for recruitment of parkin to
the mitochondria will help us to understand how the PrNKl/parkin pathway promotes
neuronal survival.
3. Mitochondria and cell survival
Mitochondria perform a range of fundamental functions in eukaryotic cells, including
supplying energy needed for the cell to do work, thereby maintaining cell function and
survival. Additionally, mitochondria are involved in the biosynthesis of amino acids,
vitamin cofactors, fatty acids, and iron-sulphur clusters, and are involved in aspects of
cell signalling (Bowsher and Tobin 200 I; Giacomello et al. 2007; Mackenzie and
McIntosh 1999). More recently, mitochondria have been highlighted as a central
mediator of signals involved in programmed cell death and their involvement in cell fate
decisions has been demonstrated in numerous diseases.
The generation of ATP (adenosine triphosphate) through the mitochondrial respiratory
chain is considered to be the primary role of the mitochondria (Figure I). ATP is the
most important molecule for capturing and transferring energy in cells, where the
hydrolysis of its phosphoanhydride bonds results in a free energy change of -7 Kcal/mol
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Figure 1. Mitochondrial Respiration and Oxidative Phosphorylation. ADP is phosphorylated to form ATP, driven by the transfer of electrons from
NADH, through the ETC and to oxygen. NADH is supplied via the oxidation of glucose and fatty acids during glycolosis, 13-oxidation and the TCA
cycle. Energy released from the ETC is used to pump protons across the mitochondrial inner membrane, generating a proton motive force which is then
used to power ATP synthesis via the return of protons down their gradient, passing through and providing energy to the ATP synthase.
(Gajewski et al. 1986). ATP enables work to be done in the cell and is involved in a
variety of pathways necessary for cell function and survival. Some of these pathways
include synthesis of macromolecules in the cell, moving substances across cell
membranes and mechanical work such as chromatin assembly or contraction of muscle
cells. ATP is used as an on-off switch for many proteins, thereby controlling enzymatic
reactions and signalling within the cell (Brown 1992). In addition to the production of
ATP, the membrane potential generated by the mitochondrial respiratory chain is
essential for the import of mitochondrial proteins and movement of metabolites (Ricci et
al. 2003). For these reasons, regulation of the respiratory chain is essential for the
maintenance of membrane potential and the supply of ATP. It is also essential for the
prevention of excessive electron loss that could otherwise result in the production of
oxygen radicals in the mitochondria (Fariss et al. 2005). A decline in ATP production
and increases in oxidative damage are important factors in mitochondrial dysfunction and
initiation of apoptosis, such that defects in the respiratory machinery or its control have
been implicated in the aetiology of numerous diseases, including Parkinson disease.
3.1 Oxidative Stress
Many neurodegenerative diseases have been linked, directly or indirectly, to oxidative
stress (Sayre et al. 2008). This is largely due to the high energy-demanding nature of
tissues in the nervous system. Deficiencies in the ability to combat or repair oxidative
damage are particularly detrimental in these tissues due to the high level of oxygen
metabolism and production of potentially damaging reactive oxygen species (ROS). ROS
are an unavoidable consequence of mitochondrial respiration, with approximately 90% of
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all ROS in the cell produced in the mitochondria (Balaban et al. 2005; Logan 2006).
Mitochondrial ROS are generated at two major sites in the electron transport chain,
complexes I and III (Figure I), where there are large changes in the potential energy of
the electrons (Chen et al. 2003; Fleury et al. 2002; Kushnareva et al. 2002). During the
transfer of electrons along these complexes, single electrons can spontaneously leak into
the mitochondrial matrix and react with molecular oxygen, forming a superoxide anion.
This superoxide is normally converted to H20 via superoxide dismutase and catalase
(Balaban et al. 2005). However, when the rate of electron transport is limited due to the
generation of a large proton gradient, an excess of free electrons occurs and the
antioxidant enzymes, as well as non-enzymatic antioxidants, may become overwhelmed.
This could lead to the generation of superoxide anions as well as other mitochondrial free
radicals including hydrogen peroxide (H202) and hydroxyl radicals (OH).
The highly reactive and short-lived nature of ROS results in localized impact, doing most
damage to the proteins, lipids and nucleic acids in the mitochondria, where they are
generated (Bras et al. 2005; Garrido et al. 2006; Wiseman and Halliwell 1996). This
mitochondrial damage can have disastrous effects in the cell, where membrane disruption
results in the release of pro-apoptotic compounds and any damage to the electron
transport chain will deplete the cell of needed ATP as well as further amplify ROS
generation. Accumulation of ROS can be alleviated by the activity of enzymatic and non-
enzymatic antioxidants in the cell. In addition, there are mechanisms to help prevent
ROS production, such as controlling over-reduction within the electron transport chain
through the regulation of respiration and through "leaking" protons down their
II
concentration gradient via uncoupling proteins (Smith et al. 2004; Starkov 2006). It is
important to realize that although ROS are typically thought of as having a toxic role in
the cell, pro-oxidative and anti-oxidative systems are in a steady state, where an excess in
either system has fatal consequences (Zorov et al. 2005). ROS should therefore be
regarded more as part of the dynamic equilibrium that allows the mitochondria to initiate
cellular life-and-death events.
Studies have shown that various metals, such as iron and copper, possess the ability to
produce ROS in biological systems, and that disruption of metal ion homeostasis can lead
to oxidative stress (Jomova and Valko 2011). The mechanism of metal-dependent ROS
formation is highly influenced by the action of cellular antioxidants such as vitamin C,
vitamin E, glutathione, and others. These antioxidants are capable of chelating metal
ions, thereby reducing their ability to form ROS. Although metal-induced oxidative
stress has been suspected previously in sporadic forms ofPD, only recently have links
been made with familial forms of PD. Studies in Drosophila have demonstrated a
sensitivity ofparkin mutants to iron and copper, with the administration of metal
chelating agents significantly improving lifespan (Saini et al. 20 10). In addition, dietary
zinc markedly improved parkin mutant phenotypes (Saini and Schaffner 20 I0). Although
the effect of zinc has been described as confusing, it is likely due to the involvement of
zinc in antioxidant enzymes such as superoxide dismutase (SOD) and catalase. Other
studies have provided evidence that substances such as coffee or tobacco can reduce the
incidence of PD and potently suppress the age-dependent loss of dopaminergic neurons
(Trinh et al. 2010). These findings have not been attributed to either caffeine or nicotine,
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and the responsible components have yet to be identified. While various studies support
the role of oxidative stress in the pathogenesis of PO, the lack of clear evidence that
antioxidant therapies can provide benefit in this disease demonstrates the need for more
therapeutic research in this area.
3.2 Increased mitochondrial membrane permeability
Mitochondrial membrane permeability resulting in the release of apoptotic factors into the
cytosol is widely accepted as a "point of no return" during apoptosis. Even in apoptotic
pathways that do not directly involve the mitochondria, such as the Fas pathway, pore
formation in the mitochondrial membranes may be used to amplify the death signal. The
precise mechanism of pore formation is still debated, as well as the importance of inner
versus outer membrane permeability in the apoptotic cascade. One model suggests that
outer membrane permeability is a consequence of the formation ofa permeability
transition pore (PTP) in the inner membrane, and therefore, the inner membrane
permeability transition is the irreversible step during apoptosis (Garrido et al. 2006).
Others argue that the mitochondrial outer membrane permeabilization (MOMP) is
independent from the PTP, and is exclusively the product of cytoplasmic proteins
belonging to the BcI-2 family. Recent research has made connections between MOMP
and mitochondrial fission, suggesting a causal relationship between the two. It is possible
that PTP, MOMP and mitochondrial fission are all mechanisms involved in increased
membrane permeability, operating independently or in cooperation to initiate
mitochondrial fragmentation and/or apoptosis.
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3.2.1 Permeability Transition Pore (PTP)
Increases in permeability observed across the mitochondrial inner membrane are widely
attributed to the opening of protein channels identified as permeability transition pores
(PTP)(Garrido et al. 2006; Green and Kroemer 2004; Mignotte and Vayssiere 1998).
These pores span both the inner and outer membranes, allowing molecules smaller than
1.5 kDa to pass between the cytoplasm and the mitochondrial matrix in a non-selective
manner (Bernardi et al. 1992). As ions and respiratory substrates equilibrate across the
membranes, a reduction in membrane potential occurs, ATP synthesis is halted, and
osmotic pressure results in the swelling of the mitochondrial matrix (Chipuk et al. 2006;
Crompton 1999; Halestrap et al. 2002). This leads to an increased permeability ofthe
outer membrane, liberation of contents from the inter-membrane space, and the eventual
rupture ofthe outer mitochondrial membrane (Zoratti et al. 2005). To illustrate the
importance of this phenomenon, it is thought that the opening ofa single pore is sufficient
to initiate all of these events.
The PTP forms at contact points between the inner and outer mitochondrial membranes,
and is thought to be composed of proteins existing within these membranes as well as in
the matrix (Figure 2). The exact composition of the PTP remains unknown, however it is
typically thought to include the voltage-dependent anion channel (VDAC) from the outer
membrane, the adenine nucleotide translocator (ANT) from the inner membrane, and
cyclophilin D (CypD) from the matrix (Crompton 1999; Crompton et al. 2002; Green and
Kroemer 2004). It should be noted that recent studies show that the ANT and CypD are
not essential for PTP formation and that Complex I may be a major component of this
14
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type of pore (Basso et al. 2005; Fontaine and Bernardi 1999; Kokoszka et al. 2004). It is
possible that many mitochondrial proteins are able to contribute to PTP formation and
that its composition is dependent on the initial stimulus.
The PTP has been shown to respond to various factors originating from both inside and
outside the mitochondria. Three established activators of the PTP include increases in
cytosolic Ca2+, reactive oxygen species, and depolarization of the inner membrane
(Giacomello et al. 2007; Kowaltowski et al. 2001; Matsuyama et al. 2000; Matsuyama
and Reed 2000). The primary activating factor appears to be Ca2+, and it is thought that
other inducers and inhibitors of the PTP operate indirectly through alteration ofCa2+
levels (Fontaine and Bernardi 1999). The association of Ca2+ with cell death via the PTP
appears to be in conflict with other studies that demonstrate the benefits of Ca2+ within
the mitochondria. It has been well established that even a very large Ca2+ release in the
cytosol, with subsequent accumulation in the mitochondria, does not trigger cell death but
is able to increase mitochondrial respiration and ATP levels in the cell. It has been
proposed that for Ca2+ to have damaging effects in the mitochondria, a "double hit" must
occur where the apoptotic stimuli responsible for triggering Ca2+ release must have a dual
target in the mitochondria, allowing for Ca2+ to act as an apoptotic signal (Pinton et al.
2001; Szalai et al. 1999). The ability of Ca2+ to both regulate respiration and aspects of
apoptosis highlight the dual role of mitochondria with respect to cell survival and cell
death.
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3.2.2 Mitochondrial Outer Membrane Permeabilization (MOMP)
The activation of apoptosis in the mitochondrial pathway requires mitochondrial outer
membrane permeabilization (MOMP), which mayor may not be discrete from formation
of the PTP. For MOMP to occur without PTP involvement, a coordinated effort between
various Bcl-2 proteins must be employed (Garrido et al. 2006). During this process,
multi-domain members of the Bcl-2 family, such as Bax or Bak, create pores in the outer
membrane, resulting in the release of soluble proteins from the inter-membrane space into
the cytosol (Figure 3). These inter-membrane proteins, such as cytochrome c, can then
activate downstream apoptotic signals resulting in cell death.
The Bcl-2 protein family contains both pro-apoptotic and anti-apoptotic proteins. The
pro-apoptotic proteins can be further broken down into those with multiple Bcl-domains,
including Bax, Bak and Bok, and those with only one domain, including Bid, Bad, Bim
and Puma, among others. For pro-apoptotic Bcl-2 proteins to initiate MOMP, the multi-
domain proteins, usually Bax or Bak, must first be activated by single domain proteins,
possibly by direct association (Kuwana et al. 2005; Letai et al. 2002). Once activated, the
Bax/Bak proteins undergo oligomerization and insertion into the outer membrane,
creating large multimeric pores and MOMP. Anti-apoptotic Bcl-2 proteins, including
Bcl-2, Bcl-xL and Mcl-I, are able to prevent pore formation by binding to the single
domain proteins, preventing their association with and activation oftheir multi-domain
counterparts (Garrido et al. 2006). Not all members of the single domain Bcl-2 proteins
are able to directly associate and activate Bax or Bak, but instead function to bind with
the anti-apoptotic Bcl-2 proteins (Chen et al. 2005). By preferentially binding, these
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Figure 3. Mitochondrial Outer Membrane Permeabilization (MOMP). Single domain Bel-2 proteins (Bid, Bad, Bim, Puma) activate multidomain,
pro-apoptotic Bel-2 proteins (Bax, Bak) resulting in their oligomerization and insertion into the outer membrane, creating large multimeric pores and
MOMP. Anti-apoptotic Bel-2 proteins (Bel-2, Bel-xL, Mel-I) inhibit pore formation by binding to single domain Bel-2 proteins, preventing their
association with and activation ofBaxlBak. Activation of Bax takes place in the cytosol with membrane insertion occurring at localized concentrations of
cardiolipin. Inactive Bak is present in the outer membrane, stabilized by VDAC until activation. During MOMP apoptotic factors are released from the
intennembranespaceintothecytosol.
single domain proteins are able to control anti-apoptotic activity and free up the other
single domain proteins that may act directly on Bax/Bak and initiate pore formation.
Bax and Bak are essential for MOMP and cells lacking these proteins are resistant to
cytochrome c release and apoptosis (Wei et al. 2001). Inactive Bax exists mainly in the
cytosol, where, upon activation, a conformational change occurs that allows for its
insertion into the outer membrane (Garrido et al. 2006). A strong association has been
found between Bax membrane insertion and localized concentrations of cardiolipin
(Lutter et al. 2000; Lutter et al. 2001). In this instance, it is thought that proteins in the
outer membrane concentrate cardiolipin when stimulated by apoptotic signals originating
from either inside or outside the mitochondria. Localization of cardiolipin at contact
points then facilitate Bax insertion into the mitochondrial outer membrane leading to
MOMP. Conversely, Bak resides within the outer membrane, but in an inactive state
thought to be stabilized though interactions with outer membrane proteins such as VDAC
(Cheng et al. 2003; Green 2005). It is not thought that these membrane proteins initiate
activation ofBak, but that the single domain BcI-2 proteins are able to disrupt the
association between membrane proteins and Bak during times of cellular stress (Cheng et
al. 2003). Taken together, it appears that the regulation of the single domain BcI-2
proteins is the critical step in formation of the MOMP. These proteins are regulated by a
variety of mechanisms in the cytosol, including cleavage by caspases in response to death
receptor stimulation (Bid), inactivation by binding to the cytoskeleton (Bim),
dephosphorylation (Bad) and upregulation by apoptotic stimulation (Puma) (Chipuk et al.
2006). Therefore, it is likely that multiple signal cascades are involved in MOMP, with
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transcriptional and post-transcriptional regulation of the single domain Bc1-2 proteins at
the heart of its activation.
3.2.3 Mitochondria/fission and MOMP
MOMP may rely on the activation ofthe molecular machinery involved in mitochondrial
fission (Frank et al. 2001). Mitochondrial fission and fusion occur in normal, non-
apoptotic cells and are essential for cellular function. In order to prevent apoptosis during
normal cellular events, such as cell division, it is important that fission proceeds in a
highly controlled manner such that leakage of soluble proteins from the inter-membrane
space, as well as the matrix, is avoided. Morphological changes associated with fission
have also been observed in MOMP during apoptosis. It has been shown that pro-
apoptotic signals are able to influence the connectivity of the mitochondrial network,
resulting in fragmentation and punctate mitochondrial morphology (Frank et al. 200 I).
Not only is mitochondrial fragmentation able to contribute to apoptosis, it is involved in
its inhibition, depending on the nature of the initial signal. Many proteins involved in
mitochondrial fission and fusion have been shown to have the ability to regulate MOMP,
where the activation of those associated with fission (Drp-l, Endophilin and Fis) are
connected with MOMP, and those associated with fusion (Fzol and Opal) are connected
with the inhibition of MOMP (Perfettini et al. 2005). As mentioned, studies indicate that
protection via the PINKI/parkin pathway is largely due to its regulation of fission/fusion
events (Chu 2010; Jendrach et al. 2009). Recruitment of parkin to the mitochondria
results in the ubiquitination of mitofusin, a Drosophila mitochondrial fusion protein,
resulting in decreased fusion and promotion ofmitophagy (Gegg et al. 2010; Ziviani et al.
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20 I0). As seen with other fission/fusion proteins, it is possible that PINK I/parkin may
also be involved in MOMP as a means of triggering apoptosis under certain conditions.
3.3 Mitochondrial Apoptotic factors
The release of various pro-apoptotic proteins from the mitochondria into the cytosol is a
well characterized event during apoptosis (Figure 4). Proteins released from the inter-
membrane space may include caspase-independent factors such as nucleases and
proteases, as well as caspase activators. The caspase dependent pathway involves the
release of cytochrome c, as well as the release of proteins such as Omi/HtrA2 and
Smac/D1ABLO which help to prevent inhibition of the caspase cascade. The caspase
independent pathway, including the AIF and Endo G proteins, typically involves direct
action on cellular components including the initiation of DNA fragmentation. Although
the mechanisms by which these mitochondrial factors are released are still debated, it is
obvious that their release is vital in the decision between cell survival and cell death.
The first protein shown to be released from the mitochondria during apoptosis was
cytochrome c; consequently it is one ofthe most investigated apoptotic proteins. Some
studies indicate that once cytochrome c release is initiated, it continues until all
cytochrome c has been released from all mitochondria within the cell (Goldstein et al.
2000). Other studies suggest that a subset of mitochondria retain their cytochrome c,
possibly to provide the ATP required for completion of the apoptotic program (D'Herde et
al. 2000). Normally a component of mitochondrial respiration, cytochrome c plays a dual
role in the cell where, upon release from the inter-membrane space, it serves to initiate the
caspase cascade. Once in the cytosol, cytochrome c forms an ATP dependent complex
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Figure 4. Release of Mitochondrial Apoptotic Factors. Release of Cyt c into the cytosol leads to fonnation of the apoptosome via association with
Apaf-1. The apoptosome recruits and activates caspase-9, which can then activate other downstream effector caspases (caspase-3 and -7) and result in
apoptosis. XIAP is able to inhibit caspase-3 and -9. OmilHtrA2 and SmaclDIABLO bind XlAP preventing inhibition of the caspases. AIF and Endo G
are released into the cytosol and translocate to the nucleus resulting in large scale DNA fragmentation. In non-apoptotic cells AIF may interact with
Complex III the ETC, facilitating the transfer of an electron to Cyt c.
with apoptotic protease-activating factor 1 (Apaf-I), resulting in the fonnation of the
apoptosome (Bras et al. 2005). This complex is able to recruit and activate seven dimers
of caspase-9, which can then activate other downstream caspases. These effector
caspases, including caspase-3 and -7, are able to activate DNases, inhibit DNA repair
enzymes, and cleave cytoskeletal proteins, mediating the biochemical and morphological
changes observed during apoptosis. The initiation of this cascade reaction is regulated by
caspase inhibitors, including inhibitor of apoptosis proteins (lAPs) such as XIAP (Bratton
et al. 2001). XIAP has been shown to bind the activated fonns of caspase-3 and -9,
thereby inhibiting the caspase cascade. Additional proteins released from the inter-
membrane space during apoptosis, Omi/HtrA2 and SmaclDlABLO, are able to overcome
the effects ofXIAP through its binding and subsequent inactivation (Gao et al. 2007;
Martins et al. 2002). It is important to note that recent findings have identified the release
of cytochrome c as essential for cellular processes including fonnation of platelets,
macrophage differentiation, Drosophila spenn cell differentiation and B-cell proliferation
(Garrido et al. 2006). It is thought that these are able to avoid the apoptotic cascade
through very specific cleavage of substrates by the caspases. The specific mechanisms
behind these processes are still unknown, however it does suggest that release of
cytochrome c is not only a regulator of cell death but of vital cellular processes.
A major contributor to caspase-independent apoptosis is apoptosis-inducing factor (AlF).
When released from the inter-membrane space during apoptosis, AIF translocates through
the cytosol to the nucleus via a nuclear localization signal (Susin et al. 2000; Susin et al.
1999). Once in the nucleus, AIF is able to bind DNA, resulting in large-scale DNA
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fragmentation and peripheral chromatin condensation. As well, the mitochondrial
endonuclease protein, Endo G, is able to work with both AIF and the caspase-activated
DNase CADIDFF40 (Bras et al. 2005). How these factors achieve chromatin
condensation and nuclear degradation is not fully understood, and may involve nuclease
activity, recruitment of other nucleases, or interaction with the DNA in such a way as to
increase its susceptibility to nucleases. Although AIF has been shown to be caspase-
independent, caspase-8 is able to induce a secondary release of AIF, and AIF is able to
increase the release of cytochrome c (Cande et al. 2002; Cho and Choi 2002). This
evidence of interaction between AIF and the caspase cascade indicates that these proteins
do not always act in discrete pathways during apoptosis. The function of AIF in non-
apoptotic cells remains elusive. Based on its similarity to prokaryotic oxidoreductases, it
is thought that AIF may interact with Complex III of the electron transport chain,
facilitating the transfer of an electron to cytochrome c (Cande et al. 2002). This proposed
dual function of AIF coincides with that of cytochrome c, and it is probable that AIF may
be involved in other cellular processes. It is very likely that more mitochondrial proteins
will be identified in the future to have roles in both cell survival and cell death.
3.4 Mitochondrial theory of ageing
The mitochondria theory of ageing proposes that oxidation is the major contributor to
cellular senescence and diseases associated with ageing. It is thought that ROS produced
during mitochondrial respiration lead to senescence by damaging mtDNA, causing further
declines in oxidative phosphorylation as well as other mitochondrial damage (Balaban et
al. 2005; Dufour and Larsson 2004). During ROS production, a positive feedback loop
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occurs where free-radical damage to mtDNA leads to respiratory dysfunction, which
leads to increased leaking of free electrons into the matrix, and therefore more ROS and
more mtDNA damage. Once cells accumulate enough damaged mitochondria, cell
function is compromised and apoptosis may be initiated. Impairment of respiration is
particularly detrimental in tissues that are critically dependent on large supplies of ATP,
including the central nervous system, heart muscle, skeletal muscle and pancreatic islets
(Chinnery and Turnbull 1997). These tissues have been shown to have accumulations of
oxidative lesions in mtDNA, and can exhibit damage to mitochondrial proteins and lipids
(Shigenaga et al. 1994). Given the sensitivity ofthese tissues, regulation of ROS
production becomes of particular importance in maintaining cellular integrity.
The large amount of lifespan variation observed between species is of great interest when
studying ageing in humans. Previous studies indicate that species with long lifespan tend
to have low rates of ROS production, low levels of oxidative damage, and membranes
that are resistant to oxidative damage (Pamplona et al. 2002). The low rates of ROS
production are usually in response to low metabolic activity in these organisms, however
there are exceptions. Birds, for example, have a very high metabolic activity associated
with longevity, and insects show low metabolic activity with short lifespan (Dufour and
Larsson 2004). Many of these exceptions can be explained by the efficiency of the ROS-
eliminating systems in these organisms, where ROS production level still seems to be the
underlying factor. In support of this theory, it has been found that increases in enzymatic
antioxidants such as superoxide dismutase, or non-enzymatic antioxidants such as vitamin
E, are able to increase lifespan in yeast, paramecium, nematodes, and mice (Dilova et al.
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2007; Dufour and Larsson 2004). Ultimately, is appears that longevity is closely
intertwined with energy production via the mitochondria, and the extent of ageing is
dependent upon the efficiency of this process.
The cellular mechanisms that control energy conservation during times of reduced food
availability may affect respiration such that ROS production is lowered and lifespan is
prolonged (Shigenaga et al. 1994). The role of the mitochondria during calorie restriction
is an active area of research that has yielded conflicting results. It has been shown that
calorie restriction is able to promote mitochondrial respiration in mice and rats, and is
able to do so with simultaneous reduction in ROS (Dilova et al. 2007; Lopez-Lluch et al.
2006). Up-regulation of mitochondrial respiration during calorie restriction has been
demonstrated in other species, supporting the idea that increased respiration is an
important feature in lifespan extension (Dilova et al. 2007). Conversely, several studies
show that a decrease in mitochondrial function, in particular a decrease in respiration,
extends lifespan (Dillin et al. 2002; Hansen et al. 2005; Lee et al. 2003). Calorie
restriction is able to decrease respiration, and has been linked to decreases in superoxide
production at complex I, as well as reduction ofmtDNA damage (Dilova et al. 2007). It
is important to note that although reduced mitochondrial respiration has been associated
with increased lifespan, it has resulted in developmental delays as well as growth and
behavioural alterations, possibly due to the catabolism of the organism's tissues (Dillin et
al. 2002; Hansen et al. 2005; Lee et al. 2003). Apart from increasing / decreasing
respiration, it has been suggested that calorie restriction acts to increase overall
mitochondrial fitness via protection and maintenance of enzymes that normally decline
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with age. Regardless of the action, for increases in longevity to occur in larger
organisms, particularly those who have passed developmental stages, calorie restriction
must be severe, making it difficult to maintain proper nutrient levels and a non-catabolic
state. For this reason, calorie restriction, at present, is not a very practical application for
lifespan extension in humans.
4. Goals of Study
In our ageing population, understanding degenerative diseases such as Parkinson disease
is essential. A need for disease-modifying therapies for PD highlight the need for
investigation into the underlying mechanisms of this disease. Although sporadic forms of
PD are more common, inherited forms share features with the sporadic and can help us to
understand disease pathogenesis and progression.
The fruit fly, Drosophila melanogaster. has proven to be an invaluable model system in
the study of human disease, including PD (Whitworth 2011). As a relatively simple
model organism, Drosophila are easy to genetically manipulate, yet they are complex
enough to allow for behavioural assays. The conservation of genetic, molecular, and cell
biology between Drosophila and humans has allowed Drosophila studies to address many
biological puzzles relevant to human health.
Research for this thesis began shortly following initial reports of an association between
mutations in PINKi and sporadic early-onset parkinsonism (Valente et al. 2004a; Valente
et al. 2004b). With no animal models at the time, it was my goal to identify a Drosophila
PiNKi homologue and study the gene within a Drosophila model ofthe disease. In
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particular, I wished to study the effects ofPinki in an a-synuclein-induced Drosophila
model of PD, which had been previously used in our laboratory to study the biological
role ofparkin. At this time no links between Pinki and other PD genes had been
identified. Therefore, my aim was to investigate the role of Pink 1 in the Drosophila
model in comparison to parkin. Moreover, I sought to use expression studies to
investigate the possible protective role ofPinki and interactions it may have with other
genes or pathways.
To explore possible roles of Pink I in the Drosophila model, I identified, characterized
and cloned a Drosophila homologue of human PiNKi (Pinki) and generated transgenic
Drosophila that can conditionally express Pinki under the control of the Gal4-responsive
VAS enhancer element. Expression studies were carried out using various neuronal and
ubiquitous Ga14 transgenes to express genes in a tissue specific manner. Biological
parameters were analyzed to observe the effects of gene expression including
morphological, longevity and behavioural effects. Initial results suggested that Pink I was
able to impart protection against protein toxicity, possibly through an interaction with
parkin. To further evaluate the protective role of these proteins, I performed studies using
Ga14 and Foxo overexpression to induce cell stress. Results from these studies
demonstrate complex roles for Pinki and parkin, and suggest that they may not act
exclusively in cell protection. It is my hope that these findings shed light on the function
of Pinkl in the cell, and help us better understand some ofthe mechanisms that underlie
the pathogenesis of Parkinson disease.
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Chapter 2
Pink] suppresses a-synuclein induced phenotypes in a
Drosophila model of Parkinson disease
A version of this chapter has been published in Genome (Todd and Staveley 2008)
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Abstract
Parkinson disease (PO) is the most prevalent human neurodegenerative movement
disorder and is characterized by a selective and progressive loss of the dopaminergic
neurons. Mutations in the genes parkin and PTEN-induced putative kinase I (PINKI)
result in autosomal recessive forms of PD. It has been suggested that parkin and Pinkl
function in the same pathway in Drosophila, with Pink I acting upstream of parkin.
Previous work in our laboratory has shown that parkin can rescue an a-synuciein-
induced PO-like phenotype in Drosophila. To investigate the ability of Pink I to
protect against a-synuciein-induced toxicity, we performed longevity, mobility, and
histological studies to determine whether Drosophila Pinkl can rescue the a-synuclein
phenotypes. We found that overexpression of Pink I results in the rescue of the a-
synuciein-induced phenotype of premature loss of ciimbing ability, suppression of
degeneration of the ommatidial array, and suppression ofa-synuciein-induced
developmental defects in the Drosophila eye. These results mark the first
demonstration of Pink I counteracting PO phenotypes in a protein toxicity animal
model, and they show that Pink) is able to impart protection against potentially
harmful proteins such as a-synuciein that would otherwise result in cellular stress.
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Introduction
Parkinson disease (PO) is the most prevalent human neurodegenerative movement
disorder and affects 1-2% of the population over the age of 65 years (Weintraub et al.
2008). Characterized by a progressive loss of dopaminergic (OA) neurons in the
substantia nigra pars compacta, PO results in age-dependent increases in
bradykinesia, muscular rigidity, gait abnormalities, and resting tremor. Pathological
characteristics of PO often include the presence of ubiquitin-positive and a-synuclein-
enriched inclusions, known as Lewy bodies, in the remaining neurons. Currently,
mutant forms of six genes have been linked to familial forms of PO, including a-
synuclein, LRRK2, uchLI, OJ-I, parkin, and PINKI (Gasser 2007). Although
sporadic forms of PO are believed to be more common, 5-15% of PO cases are of an
inherited nature, and many of these familial forms share features with sporadic PO,
including oxidative stress, protein aggregation and mitochondrial dysfunction
(Dawson and Dawson 2003). For this reason, understanding the mechanisms behind
familial forms of PO may also help us to understand sporadic forms of PD.
Mutations in the gene PINKI (PTEN induced putative kinase I) result in a form of
autosomal recessive PO and mutations in PINK I have been detected in sporadic cases
of the disease (Valente et al. 2004a; Valente et al. 2004b). Identified as a kinase,
PINK I has been shown to locate to the mitochondria and is hypothesized to be
involved in mitochondrial protection. Mutations in PINKI, and in the Drosophila
homologue Pink!, show substantial mitochondrial defects in sensitive tissues (Clark et
al. 2006; Exner et al. 2007; Park et al. 2006; Yang et al. 2006). Studies support a role
for PINK I in the inhibition of the release of cytochrome c from the mitochondria
(Petit et al. 2005; Wang et al. 2007) and indicate that PINK I is important in
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preventing oxidative damage, since mutations result in oxidative stress and a decrease
in complex I activity (Hoepken et al. 2007). Complex I dysfunction is a common
feature of sporadic PO, resulting in increased oxidative stress within the mitochondria
and eventual mitochondrial dysfunction (Schapira 2008). Additionally, there is
evidence supporting the involvement of PINKI in the maintenance of the
mitochondrial membrane potential and therefore mitochondrial function (Wood-
Kaczmar et al. 2008). It is becoming clear that PINKI has a role in mitochondrial
protection, but the underlying mechanism and the relationship of PINK 1 with other
genes involved in PO are unknown.
Overexpression of the gene encoding a-synuclein has been shown to be an inherited
cause of PO, and a transgenic a-synuclein model in Drosophila has been successfully
used to mimic the degenerative processes seen in PO (Feany and Bender 2000;
Whitworth et al. 2006). Moreover, a-synuclein pathology appears to be mediated by
mitochondrial dysfunction (Hsu et al. 2000; Martin et al. 2006). Previous work in our
laboratory has shown the ability of parkin overexpression to rescue an a-synuclein
induced PO-like phenotype in Drosophila, presumably through targeting the a-
synuclein protein for degradation (Haywood and Staveley 2004). Additionally, Pink I
has recently been shown to protect neurons from the dopaminergic neurotoxin MPTP
(Haque et al. 2008), where the pathology of MPTP is attributed to the a-synuclein
protein (Dauer et al. 2002; Klivenyi et al. 2006). It has been suggested that parkin and
Pink! function in the same pathway and that this Pinkl/parkin pathway is necessary
for proper mitochondrial function and morphology (Clark et al. 2006; Park et al. 2006;
Poole et al. 2008). To further investigate the possibility of Pink1 acting in this
pathway, we have performed longevity, mobility and histological studies to determine
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the effects of overexpression of Drosophila Pink I and its ability to rescue the (1-
synucleinphenotypes.
Materials and Methods
Bioinformatic sequence analysis
The Drosophila melanogaster homologue of PINK 1 was identified with the tblastn
algorithm (Altschul et at. 1990; Camacho et at. 2009) of the National Center for
Biotechnology Information (NCBI) using the theoretical translation of human PINKI,
NM_032409.2. The Mus musculus (BC067066.1), Danio rerio (BC 165767.1),
Caenorhabditis elegans (NM_0626 I6.3), and Anopheles gambiae (XM_313587.4)
homologues of Pink 1 were identified with the tblastn algorithm using the theoretical
translation of the Drosophila melanogaster homologue GH2093I cDNA. A multi-
alignment of the homologues was constructed using the ClustalW2 package of the
European Bioinformatics Institute (Larkin et at. 2007). Mitochondrial targeting motifs
were identified using MitoProt of the Institute of Human Genetics (Claros and
Vincens 1996). The kinase domains and active sites were identified using
InterProScan of the European Bioinformatics Institute (Quevillon et at. 2005).
Molecular biology
A clone of the Drosophila melanogaster Pink I cDNA (GH20931) was obtained from
Research Genetics (Rubin et at. 2000) and was sub-cloned into the pUAST vector to
generate the VAS-Pinkl transgene. Transgenic lines were created using heat shock 1t
as a source of transposase and standard injection techniques (Binari et at. 1997) into
w///8 Drosophila melanogasterembryos.
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Fly stocks and culture
Dr. M. Feany (Harvard Medical School) generously provided UAS-a-synllclein flies
(Feany and Bender 2000) and Dr. J. Hirsh (University ofYirginia) the Ddc-Ga/4 flies
(Li et al. 2000). The GMR-Ga/4 flies (Freeman 1996) were obtained from the
Bloomington Drosophila Stock Center at Indiana University. The UAS-a-synllclein;
UAS-Pink] line was generated using standard techniques. To drive expression of the
transgenes, Ddc-Ga/4 (for expression in the dopaminergic neurons) or GMR-Ga/4 (for
expression in the eye) homozygous females were crossed to w///8 males (control) or
UAS-a-synllclein with or without UAS-Pink].
Ageing analysis
Two hundred adult males of each genotype were collected under gaseous carbon
dioxide and aged upon standard commeal/yeast/molasses/agar media, at 25°C, in
upright standard plastic shell vials. Flies were maintained in non-crowded conditions
with I to 20 individuals per vial. Flies were scored for viability every two days and
transferred to fresh media. Resulting survival curves were compared via logrank test.
Locomotion assay
Forty adult males of each genotype were assayed for climbing ability (Todd and
Staveley 2004). Flies were maintained on standard commeal/yeast/molasses/agar
media at 25°C and were assayed every seven days. Climbing ability was determined
via non-linear curve fit within a 95% confidence interval (CI).
Scanning electron microscopy ofthe Drosophila eye
Flies of each genotype were aged on standard commeal/yeast/molasses/agar media at
29°C. These were then frozen at -70°C and examined under a dissecting microscope.
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Flies were mounted, desiccated overnight and coated in gold before photography at
150 times magnification with a Hitachi S-570 SEM. Area of the eye was measured
based on the presence of ommatidia. Ommatidia with an area greater than 150% of
normal ommatidia were classified as fused or enlarged. For each condition at least six
representative flies were analyzed.
Histological examination ofDrosophila adult retinas
Adult flies were aged on standard commeaVyeast/molasses/agar media at 25°C.
Heads of the flies were removed, fixed in Karnovsky's fixative and embedded in epon.
Tangential retinal sections were prepared for 8 flies of each genotype, at a thickness of
0.5 J.I1l1. Sections were stained with toluidine blue, examined by light microscopy and
photographed at magnification of 800 times. The extent of ommatidiaI disruption is
represented by the percentage of ommatidia exhibiting vacuolization and architectural
distortion.
Results
The Drosophila melanogaster Pink] retains functional domains found in
mammalian,fish, and invertebrate homologues
Drosophila Pinkl encodes a theoretical protein of 721 amino acids (Figure I).
Alignment of Drosophila Pinkl with vertebrate and invertebrate homologues using
CiustalW2 reveal that both the mitochondrial targeting motif and the serine/threonine
protein kinase domain are well conserved in their relative sequence / position in the
protein. Although there is variation in length of the mitochondrial targeting motif, all
homologues score 91 % and above by MitoProt for predicted location to the
mitochondria.
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Figure I. Pink 1 sequence alignments of Homo sapiens, Mus musculus, Danio rerio, Caenorhabditis
e1egans, Anopheles gambiae, and Drosophila melanogaster. Red shading indicates the mitochondrial
targeting motif. The serine/threonine protein kinase, catalytic domain is indicated by the blue shading,
with the active site outlined in box A. Similarity is indicated as identical (O),conservedsubstitutions
(:),andsemi-conserved substitutions (.). Aminoacidcoloursindicateacidic(blue),basic(magenta),
basic-hytroxyl lamine(green),andsmall-hydrophobic including aromatic{red).
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Pink] rescues the a-synuclein induced phenotype ofpremature decreased
climbing ability
Drosophila melanogaster exhibit a strong negative geotactic response and, when
stimulated, will immediately climb towards the top of a vial (Le Bourg and Lints
1992). This response decreases with age to result in shorter, more sporadic climbs as
well as an increased number of failed climbing attempts. Transgenic flies that express
a.-synuclein, in response to either a pan-neural (elav-GaI4) or a dopaminergic neuronal
(Ddc-GaI4) transgene, prematurely develop this locomotor dysfunction (Figure
2A)(Feany and Bender 2000). This results in a functional impairment that provides an
experimentally versatile Drosophila model of Parkinson disease. Our results show
that within this a.-synuclein-induced model, directed overexpression of Pink I to the
dopaminergic neurons results in the complete suppression of the premature loss in
climbing ability (Figure 2A). These results suggest that with the expression of Pink I,
the dopaminergic neurons are able to overcome the damaging effects of a.-synuclein.
Directed overexpression of Pink I alone does not have a significant effect on climbing
ability (Figure 2A). Neuronal expression of a.-synuclein and / or overexpression of
Pink I do not alter lifespan (Figure 28), indicating that changes observed are due to
differences in mobility and are not due to premature senescence.
Pink] suppresses a-synuclein-induced developmental defects in the eye
GMR-GaI4 heterozygotes raised at 25°C have a rough eye phenotype that is enhanced
when the flies are raised at 29°C (Figure 3A) (Kramer and Staveley 2003). At 29°C,
the severity of this rough eye phenotype increases with the expression of a.-synuclein
(Figure 3C, E), to suggest that the presence of a.-synuclein further interferes with
normal ommatidial development. By overexpressing Pinkl with a.-synuclein in the
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Figure 2. Pinkl rescues the a-synllclein induced phenotype of premature decreased c\imbingability.
Overexpression of Pink 1 in the dopaminergic neurons via Ddc-Gal4 results in increased mobility and
rescueofthea-synllcleininducedphenotype(A). LongevityoffliesexpressingPink/and/ora-
synllclein do not differ from control flies (8). Genotypes are (Control) W11l8; +1+; Ddc-GaI4/+. (Pink!)
W" 18; +1+; UAS-PinkI/Ddc-GaI4, (aSYN) W" 18; UAS-a-synllclein/+; Ddc-Ga/4/+, and (aSYN;Pinkl)
w" 18; UAS-a-synllclein/+; UAS-PinkIlDdc-GaI4. Longevity is shown as percent survival (p<O.05 as
determined by log rank). Climbing ability was determined via non-linear curve fit (CI = 95%). Error
bars indicate standard error.
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Figure 3. Pinkl suppressesa-synucleininduceddevelopmentaldefectsintheeye. Rougheye
phenotype present at 29°C with GMR-Ga/4 (A). Ultra-structure disarray is increased with a-synllclein
expressionandissuppressedwithoverexpressionofPink/ascomparedto both a-synllcleinand the
control (A-E). The genotypes are (A) WillS; GMR-Ga/4/+. (8) WillS; GMR-Ga/4/+; VAS-Pink/I+, (C)
WillS; GMR-Ga/4/VAS-a-synllclein, and (D) WillS; GMR-Ga/4/VAS-a-synllclein; VAS-Pink//+. (A-D)
scanning electron micrographs (SEM). (E) Percent of eye area containing fused or enlarged (>150%)
ommatidia. Error bars indicate standard error.
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developing eye, a partial suppression of the rough eye phenotype is observed, such
that the level of ultra-structure disruption is reduced to control levels (Figure 3D, E).
Additionally, overexpression of Pink I partially suppresses the rough eye phenotype of
the control (Figure 3B, E). These results suggest that overexpression of Pink 1 is not
only able to counteract the effects of a-synuclein in the developing eye, but also, to
some extent, the effects ofGal4.
Pink} suppresses a-synuclein-induced degeneration ofthe ommatidial array
To observe neuronal degeneration over time, the a-synuclein model was used to
observe degeneration of the Drosophila ommatidial array. As previously described,
cross-sections of the retinas of Drosophila expressing a-synuclein in the developing
eye are intact at three days old, with premature deterioration of the retina at thirty days
old (Figure 4C, G, I) (Feany and Bender 2000). As compared to the control (Figure
4A, E, H), overexpression of Pink1 in the developing eye (Figure 4B, F, I) results in
no significance difference in retinal degeneration. When Pink1 isoverexpressed
within the a-synuclein model, intact retinas are seen at three-days-old and this
morphology is maintained at thirty-days-old (Figure 4D, H, I). These results
demonstrate the ability of Pink1 overexpression to suppress the a-synuclein-dependent
degeneration of the ommatidial array, further supporting the participation of Pink 1 in
overcoming the detrimental effects of the a-synuclein protein.
Discussion
The a-synuclein protein is a central pathogenic mechanism leading to oxidative stress
(Dauer et al. 2002), and a-synuclein accumulation has been associated with
mitochondrial Complex I dysfunction (Betarbet et al. 2006; Fomai et al. 2005). Even
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Figure 4. ExpressionofPinklsuppressesa-synuclein-induccdretinaldegeneration.Fliesexpressing
a-synllcleinhaveintactretinasat3daysoldwithdeteriorationoftheretinaat30daysold(C,G,I).
Flies overexpressing Pink/ with a-synllclein show intact retinas at 3 and 30 days old (D, H, I). The
genotypes are (Control) W'llS; GMR-Ga/4/+. (Pinkl) WillS; GMR-Ga/4/+; VAS-Pinkll+, (aSY ) WillS;
GMR-Ga/4/VAS-a-synllclein, and (aSY ;Pinkl) willS; GMR-Ga/4/VAS-a-synllclein; VAS-Pink/I+.
(A-D) 3 day old flies, (E-H) 30 day old flies. (I) Percent of disrupted ommatidia present in the
ommatidial array. Error bars indicate standard error. Arrows indicate degeneration of the ommatidial
architecture.
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a slight elevation in u-synuclein levels can lead to neuronal toxicity (Ibanez etal.
2004), and it has been suggested that u-synuclein is able to disrupt a range of nonnal
cellular functions through the fonnation of cellular protein aggregates (Mukaetova-
Ladinska and McKeith 2006). In addition, oligomerized fonns of the protein may also
lead to toxicity by fonning pores within cellular membranes (Volles et al. 2001).
Although the exact pathogenesis of u-synuclein remains unclear, it has been
successfully used to mimic the degenerative processes seen in Parkinson disease.
This study marks the first demonstration of Pink I counteracting the phenotypic effects
ofu-synuclein toxicity in an animal model. The ability ofPinkl to suppress the
effects of u-synuclein are similar to those observed with parkin (Haywood and
Staveley 2004), supporting the theory that Pinkl and parkin act in a common pathway
(Clark et al. 2006; Park et al. 2006; Poole et al. 2008). It is possible that Pink I may
activate parkin directly or indirectly, thereby activating the ubiquitin-proteasomal
system, to result in the tagging of u-synuclein for degradation. Pink I may operate to
protect the mitochondria through an interaction with molecular chaperones, since
PINK I has been shown to phosphorylate the mitochondrial chaperone TRAP I
(Hsp75), thus protecting mitochondria against oxidative stress and preventing
cytochrome c release (Pridgeon et al. 2007). In support of chaperone involvement, u-
synuclein toxicity in Drosophila is able to be partially rescued by co-expression of
molecular chaperones, namely Hsp70 (Auluck et al. 2002). Although the
identification of PINK I targets is in its infancy, the ability ofPinkl to suppress
phenotypes in a toxic protein model may suggest a broad role for Pinkl in
mitochondrial protection and the existence of targets that serve to protect against toxic
proteins such asu-synuclein.
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Chapter 3
Expression of Pink] with a-synuclein
in the dopaminergic neurons of Drosophila leads to
increases of both lifespan and healthspan
A version of this chapter has been submitted to Genetics and Molecular Research
(Todd and Stavely 201 1)
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Abstract
Overexpression of the gene coding a-synuclein has been shown to be an inherited
cause of Parkinson disease. Our laboratory has previously used the genes parkin and
Pink} to rescue a-synuclein-induced phenotypes within a Drosophila model. To
further investigate the effect of Pink} in this model, we have performed longevity and
behavioural studies using various driver lines to express the a-synuclein and Pink}
genes. Our findings show that overexpression of Pink} and overexpression of Pink}
with a-synuclein result in an increased lifespan when driven with the TH-Gal4
transgene. This increase in longevity is accompanied with increased healthspan, as
measured by mobility, suggesting that this is an example of improved functional
ageing. Our results indicate that, in the dopaminergic cells targeted by TH-Gal4,
increased expression of a-synuclein and Pinkl together have a synergistic effect,
allowing for enhanced protection and increased survival of the organism.
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Introduction
Parkinson disease (PO) affects 1-2% of the population over the age of 65 years, where
age is the largest risk factor for the development and progression of the disease (Lees
et al. 2009). PO is characterized by a progressive loss of dopaminergic neurons in the
substantia nigra pars compacta, often including the presence of ubiquitin-positive and
u-synuclein-enriched inclusions, known as Lewy bodies, in the remaining neurons.
Several genes have been linked to familial forms of PO, including the genes encoding
u-synuclein and PTEN induced putative kinase) (PINK)).
PINK) has been shown to locate to the mitochondria and is hypothesized to be
involved in mitochondrial protection (Deas et al. 2009). Mutations in PINK], and in
the Drosophila homologue Pink!, show substantial mitochondrial defects in sensitive
tissues, with the inability to inhibit cytochrome c release under stress conditions
(Clark et al. 2006; Exner et al. 2007; Park et al. 2006; Wang et al. 2007; Yang et al.
2006). As a protective protein, PINK) may confer protection of the mitochondria
through several mechanisms (Deas et al. 2009), including an interaction with
molecular chaperones to regulate oxidative stress responses, activation of the parkin
E3 ubiquitin ligase to result in the tagging of toxic proteins, such as u-synuclein, for
degradation, or through the initiation of fission events to remove dysfunctional
mitochondria via mitophagy.
Overexpression of the gene encoding u-synuclein has been shown to be an inherited
cause of PO, and a transgenic a-synuclein model in Drosophila has been successfully
used to mimic the degenerative processes seen in PO (Feany and Bender 2000;
Whitworth et al. 2006). Previous work in our laboratory has shown the ability of
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parkin overexpression and Pink! overexpression to rescue an a-synllc!ein-induced
PO-like phenotype in Drosophila me!anogaster, presumably through the targeting of
the a-synuclein protein for degradation (Haywood and Staveley 2004; Todd and
Staveley 2008). To further investigate the effect of Pink! in this model, we have
performed longevity and behavioural studies using several neuronal and ubiquitous
drivers to express the a-synllc!ein and Pink! transgenes.
Materials and Methods
Fly stocks and culture
Dr. M. Feany (Harvard Medical School) generously provided UAS-a-synllc!ein flies
(Feany and Bender 2000) and Dr. J. Hirsh (University ofYirginia) provided the Dopa
decarboxy!ase-Ga/4 (Ddc-Ga!4) flies (Li et al. 2000) and the Tyrosine Hydroxy!ase-
Gal4 (TH-Ga/4) flies (Friggi-Grelin et al. 2003). The UAS-Pink} transgenic line was
created previously using the GH2093I Drosophila me!anogaster Pink} clone (Todd
and Staveley 2008). The VAS-a-synllc!ein; VAS-Pink! line was generated using
standard techniques. The w ll18 flies were obtained from Dr. Howard Lipshitz at the
Hospital for Sick Children in Toronto. The GawBC739-Ga!4, GawBV55-Ga/4, E!av-
Ga/4, arm-Ga/4 and UAS-GFP were obtained from the Bloomington Drosophila
Stock Center at Indiana University. All flies were cultured on standard
cornmeal/yeast/molasseslagar media at 25°C.
Ageing analysis
Two hundred adult males of each genotype were collected under gaseous carbon
dioxide and aged upon standard cornmeal/yeast/molasseslagar media, at 25°C, in
upright standard plastic shell vials. Flies were maintained in non-crowded conditions
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with I to 20 individuals per vial. Flies were scored for viability every two days and
transferred to fresh media. Resulting survival curves were compared via logrank test.
Locomotion assay
Forty adult males of each genotype were assayed for climbing ability (Todd and
Staveley 2004). Flies were maintained on standard cornmeal/yeast/molasses/agar
media at 25°C and were assayed every seven days. Climbing ability was determined
via non-linear curve fit within a 95% confidence interval (CI).
Results
Overexpression of Pinkl increases lifespan when driven with TH-GaI4 (Figure lA). In
addition, overexpression of Pinkl with a-synllclein, using the TH-GaI4 driver, results
in a dramatic increase in lifespan. The results suggest that increases in expression of
a-synllclein and Pinkl together can have a synergistic effect, allowing for enhanced
protection and increased survival. When assessing the extension oflifespan observed
in Figure lA, it is necessary to determine if this is accompanied by improved
healthspan, or functional ageing, in the surviving individuals. Drosophila
melanogaster exhibit a strong negative geotactic climbing response, allowing for the
conduct of mobility assays within the a-synllclein-induced model (Haywood and
Staveley 2004; Todd and Staveley 2008). When we assessed the climbing ability of
flies expressing Pinkl, using the TH-GaI4 driver (Figure IB), there was a rescue of
the characteristic a-synllclein-induced phenotype of premature loss of climbing
ability. In addition, flies expressing Pinkl with a-synuclein using the TH-GaI4 driver
showed significant increase of climbing ability in the surviving flies as compared to
other genotypes of the same age. This suggests that the increase in longevity is an
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Figure 1. Effect of Pink} and a-synuclein expression on longevity (A) and mobility (B) when driven with
TH-Ga/4. Overexpression of Pink} using the TH-Ga/4 driver shows an increase in lifespan (mean = 72
days) as compared to controls (mean = 61±1 days), p<O.OOOI (A). Overexpression ofPink} with a-
synuclein using the TH-Ga/4 driver shows a dramatic increase in lifespan (mean = 86 days) as compared to
controls (mean = 61±1 days), p<O.OOOI. Overexpression of Pink} results in a rescue of the a-synuclein-
induced premature loss of climbing ability when driven with TH-Ga/4 (B). Overexpression ofPink} with a-
synuclein, using TH-Ga/4, shows significantly increased climbing ability above that of controls (Non-linear
curve fit comparison, CI=95%). Survival curves were compared using the Log-rank Test. Genotypes
expressed include WillS (Control 0), UAS-GFP/+ (Control G), UAS-a-synuclein/+ (a-syn), UAS-Pinkl/+
(Pinkl), UAS-a-synuclein/+; UAS-Pinkl/+ (u-syn + Pink I). Error bars indicate standard error of the mean.
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example of healthy ageing, and that the lifespan differences observed between Pink!
with a-synuclein, versus Pink! expression alone, is a synergistic effect.
To investigate the effect of a-synuclein and Pink! expression in other cell populations,
longevity studies were performed using a variety of established constitutive drivers
(Figure 2). The significant increases in lifespan shown with TH-GaI4 (Figure IA)
were not observed when using other drivers, including neuronal (GawSc739-GaI4,
GawBV55-Gal4, Elav-GaI4) and ubiquitous (Arm-GaI4) drivers (Figure 2A, B, C and
D respectively). This suggests that the increases in longevity are dependent on
expression within the dopaminergic neurons targeted by TH-GaI4.
Discussion
Our findings show that expression of Pink! with a-synuclein has a synergistic effect
when driven with the TH-GaI4 transgene, leading to increased longevity in
Drosophila. Healthspan, as measured by climbing ability over time, is also enhanced,
suggesting an improvement of functional ageing in these flies, opposed to longevity
alone. This protective effect is of interest, as a-synuclein is involved in a central
pathogenic mechanism for Parkinson disease and has been linked to various aspects of
mitochondrial dysfunction (Schapira and Gegg 20 II). Previous studies indicate that
accumulation of a-synuclein in the mitochondria of mammalian dopaminergic neurons
leads to reduced mitochondrial complex I activity and increased production of reactive
oxygen species (ROS) (Devi et al. 2008; Liu et al. 2009). It is important to note that
ROS also act as signalling molecules, and can be involved in a number of pro-survival
pathways, including regulation of autophagy (Scherz-Shouval and Elazar 2007; Weber
and Reichert 20 I0). In this respect, a-synuclein can be involved in the tumover of
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Figure 2. Effect of Pinkl and a-synuclein expression on longevity when driven with GawBC739-Ga/4 (A),
GawB V55-Ga/4 (B), E/av-Ga/4 (C) and arm-Ga/4 (D). Survival curves were compared using the Log-rank
Test. Genotypes expressed include W IIlX (Control 0), UAS-GFP/+ (Control G), UAS-a-synuclein/+ (a-syn),
UAS-Pinkl/+ (pinkl), UAS-a-synuclein/+; UAS-Pinkl/+ (a-syn + Pinkl). Error bars indicate standard error
of the mean.
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mitochondria by autophagy, or mitophagy, acting in unison with Pinkl in a pro-
survival role via the removal of defective mitochondria.
The increases in lifespan shown with TH-Gal4 were not observed when using other
drivers, including neuronal (Elav-Gal4. GawSc739-Gal4. GawSV55-Gal4) and
ubiquitous (Arm-Gal4) drivers. Within the cell, tyrosine hydroxylase enzyme
catalyzes the conversion of I-tyrosine to I-dopa, which is the initial and rate-limiting
step in the biosynthesis of catecholamines such as dopamine. These dopaminergic
neurons are particularly sensitive, perhaps exacerbated by the metabolicstresscreated
by sustained Ca2+ entry during signalling (Surmeier et al. 20 I0). Pinkl may have a
more pronounced protective effect in this particular cell type, as Pink I acts in a
general protective role but can also directly regulate calcium flux through the
mitochondria (Deas et al. 2009). Interestingly, previous work in our laboratory
expressing a-synuclein and Pink] using Ddc-Gal4 (Todd and Staveley 2008) has not
shown the synergistic effect seen in this study, using TH-Gal4. Dopa decarboxylase
catalyzes the last step of dopamine synthesis, I-dopa to dopamine, and the last step of
serotonin synthesis, I-tryptophan to serotonin. The discrepancy between results seen
when using the TH-Gal4 driver and the Ddc-Ga14 driver may be due to differences in
the amount of Pink I produced, or possibly due to differing coverage of the
dopaminergic neurons. There is growing evidence that although all dopaminergic
neuron clusters in the fly brain seem to be targeted by the TH-Gal4 driver, they are not
covered equally, and that Ddc-Gal4 likely does not target all dopaminergic neuronal
clusters (Yarali and Gerber 20 I0). This incomplete overlap of dopaminergic neurons
targeted by the TH-Gal4 and Ddc-Gal4 transgenes may indicate that there is a
particulardopaminergiccellclusterresponsiblefortheincreased lifespan observed in
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this study. It will be important for future studies to examine the differences between
the TH-GaI4 and Ddc-Gal4 drivers with respect to ageing and functional longevity.
Our results suggest that increases in o.-synllclein and ?inkl together can have a
synergistic effect, allowing for enhanced protection and increased functional longevity
in Drosophila. This may be a result of the upregulation of pro-survival mechanisms
via Pinkl, in response to an increase in ROS signalling due to o.-synllclein
overexpression. The restriction of these results to TH-GaI4-expressing cells likely
reflects the existence ofa dopaminergic cell cluster that isparticularlysensitiveto
changes in ?inkl and o.-synllclein expression. Moreover, the results indicate the need
for future examination of this particular cell population, where findings may shift
therapeutic efforts towards a particular dopaminergic cluster.
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Table 81. Lifetime survival data presented at 20 day age-intervals (I). Table indicates number entering the
age-interval (Nx) and number dead within the age interval (Dx). Genotypes expressed include wlJlS
(Control 0), UAS-GFP/+ (Control G), UAS-a-synuclein/+ (u-syn), UAS-Pinkl/+ (pinkl), UAS-a-
synudein/+; UAS-Pinkl/+ (u-syn + Pinkl).
B GawBC739 Gal4
Control 0 ControlG I--~~
Pinkl f ~i~~~~ ~---;-~ I Nx ~---;-~
r---o'200----O ----0200r---o r---o'200----0 ----0200r---o r---o'200----0
20 179 21 20 196 4 20 193 7 20 184 16 20 190 10
40 174 26 40 192 8 40 173 27 40 181 19 40 188 12
60 67 133 60 108 92 60 72 128 60 121 79 60 159 41
80 17 183 80 19 181 80 5 195 80 78 122 80 119 8\
100 8 192 100 I 199 100 2 198 100 32 168 100 35 165
120 0 200 120 0 200 120 0 200 120 0 200 120 0 200
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20 198 2 20 196 4 20 196 4 20 195 5 20 195 5
40 163 37 40 137 63 40 167 33 40 143 57 40 194 6
60 65 135 60 43 157 60 94 106 60 45 155 60 81 119
80 4 196 80 4 196 80 3 197 80 0 200 80 29 171
100 0 200 100 0 200 100 2 198 100 0 200
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I Nx dx
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Chapter 4
Pink] and parkin demonstrate multifaceted roles when co-
expressed with Foxo
A version of this chapter has been submitted to European Journal ofNeuroscience (Todd
and Staveley 2011)
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Abstract
Pinkl has been linked to both autosomal recessive and sporadic forms of Parkinson
disease. The Pink I protein is thought to be involved in mitochondrial protection by
interacting with parkin to prevent oxidative damage, through maintenance of
mitochondrial integrity and regulation of mitophagy. To further investigate the roles of
Pinkl/parkin during cell stress, we have performed co-expression studies to determine the
effects Pinkl and parkin on the Foxo-induced phenotype of developmental defects in the
Drosophila eye. Although direct and indirect links have been made between Pinkl/parkin
and insulin receptor (INR) pathway components PTEN, Akt and Foxo, the effects of
Pinkl/parkin in the INR pathway have been largely overlooked. Overexpression ofFoxo
in the Drosophila eye leads to a characteristic phenotype of reductions in cell size and cell
number. We looked at the ability ofPinkl and parkin, as protective proteins, to rescue
this phenotype. We examined directed expression of Pinkl, parkin, Pinkl or parkin
mutants, and Pinkl or parkin interfering RNAs (RNAi) with the overexpression of Foxo
in the developing eye of Drosophila. Unexpectedly, our findings show that reduction of
Pinkl suppresses the effects of Foxo overexpression, where co-overexpression with Pinkl
or parkin increases the severity of the phenotype. This suggests that Pinkl and parkin are
able to increase the effects ofFoxo. Contrary to the view that Pink I and parkin act
exclusively as protective proteins in the cell, it is likely that the Pinkl/parkin pathway is
involved in aspects of cell fate decisions other than degrading toxic proteins and
maintaining mitochondrial integrity.
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Introduction
Pink1 (PTEN induced putative kinase 1) encodes a serine-threonine kinase which has
been linked to autosomal recessive and some sporadic forms of Parkinson disease
(Jendrach et al. 2009; Valente et al. 2004a; Valente et al. 2004b). Targeted to the
mitochondria, Pinkl is thought to be involved in mitochondrial protection by preventing
oxidative damage and maintaining mitochondrial integrity, where loss of function of
Pinkl, in humans and in Drosophila melanogaster, show substantial mitochondrial
defects in sensitive tissues (Clark et al. 2006; Exner et al. 2007; Hoepken et al. 2007; Park
et al. 2006; Yang et al. 2006). In addition to maintaining and stabilizing mitochondrial
networks, it is becoming increasingly apparent that protection during cell stress is due to
the involvement of Pink I in mitochondrial fission/fusion events (Chu 2010; Jendrach et
al. 2009). This involvement implicates Pink I as a key regulator of the fission/fusion
balance, using the process ofmitophagy to specifically process and degrade dysfunctional
mitochondrial fragments.
The E3 ubiquitin ligase, parkin, acts downstream of Pink I and is thought to operate in a
Pinkl/parkin pathway necessary for proper mitochondrial integrity and function (Clark et
al. 2006; Park et al. 2006; Poole et al. 2008; Yang et al. 2008). In this role, recruitment of
parkin to the mitochondria by Pinkl results in the ubiquitination of various mitochondrial
proteins, promoting mitophagy (Gegg et al. 20 10; Geisler et al. 20 I 0; Vives-Bauza et al.
2010; Ziviani et al. 2010). In contrast, studies have found that loss of parkin or Pinkl
function can result in increased fission, promoting mitophagy (Dagda et al. 2009; Lutz et
al. 2009). Although the fission/fusion decision is not fully understood, it does suggest
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that the protective properties of parkin are not only due to tagging of cytosolic proteins
for degradation, but by direct interaction with PinkI to maintain mitochondrial
homeostasis.
Under conditions of oxidative stress or starvation, Foxo transcription factors are
activated, targeting genes that promote cell cycle arrest, stress resistance, or apoptosis
(Greer and Brunet 2005). To further investigate the roles ofPinkl/parkin during cell
stress, we have performed expression studies to determine the effects of Pink] and parkin
on the Foxo-induced phenotype of developmental defects in the Drosophila eye. The
involvement ofPinkl/parkin in the insulin receptor (JNR) pathway has been largely
overlooked, but clues to possible interactions include: interaction ofPTEN with PinkI
(Unoki and Nakamura 2001) and OJ-I (Kim et al. 2005; Kim et al. 2009), an indirect
interaction with Akt through parkin (Fallon et al. 2006), an interaction with Akt through
OJ-I (Aleyasin et al. 20 10; Yang et al. 2005), and transactivation of Pink] by Foxo (Mei
et al. 2009; Sengupta et al. 2011). We hypothesized that through an interaction with the
JNR pathway, or through mitochondrial protective effects, Pink] and parkin would be
capable of alleviating the detrimental effects of Foxo overexpression. In contrast, our
findings show that reduction of Pink] is able to suppress the effects of Foxo
overexpression, where co-overexpression ofFoxo with Pink] or parkin results in an
increased severity of the Foxo-induced phenotype. These findings suggest a complex role
for the Pinkl/parkin pathway.
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Materials and Methods
Fly stocks and culture
The VAS-Pinkl transgenic line was created from the GH2093I Drosophila melanogaster
Pink I clone (Todd and Staveley 2008). The VAS-murine Foxol (VAS-Foxo) and VAS-
murine FoxolAA (VAS-FoxOAA ) transgenes are described in Kramer et al. (2003) and the
GMR-Ga14 VAS-Foxo and GMR-GaI4;VAS-FoxoAA lines were established through
standard means. VAS-parkin was created previously in our laboratory (Haywood and
Staveley 2004). The Pinkl 89 mutant line was provided by Dr. J. Chung (Park et al. 2006).
The VAS_Pinkl RNAi and VAS_parkin RNAi lines were provided by Dr. B. Lu (Yang et al.
2006; Yang et al. 2003). The VAS-GFP control was obtained from the Bloomington
stock centre. The parkin45 mutant line was provided by Dr. L. PalIanck (Greene et al.
2003). AlI crosses were performed using standard techniques. AlI flies were cultured on
standard cornmeal/yeast/molasses/agar media at 25°C.
Scanning electron microscopy ofthe Drosophila eye
Flies were aged three days past eclosion on standard cornmeal/yeast/molasses/agar media
at 25°C. Flies were then frozen at -80°C and examined under dissecting microscope.
Flies were mounted, desiccated overnight and coated in gold before photography at 170
times magnification with a Hitachi S-570 SEM. Area of the eye was measured as per the
ocular area, regardless of the presence of ommatidia. This was determined by outlining
the ocular margin and/or ridge bristles indicating the postocular area. Eye areas and
ommatidial counts were compared using GraphPad Prism 5, using unpaired t-test.
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Results
parkin increases the severity ofthe Foxo-induced phenotype
Overexpression ofFoxo in the developing Drosophila eye results in a characteristic
phenotype with reductions in ceIl number and area (Kramer et al. 2003). When co-
overexpressed with parkin, there is a significant increase in the severity of the Foxo-
induced phenotype (Figure 1), including a significant reduction in number of ommatidia
and overaIl area ofthe eye (p<0.0001, df=31). This suggests that the addition ofparkin
further reduces the number of viable ceIls available during eye development. Co-
overexpression with Pinkl shows no significant increase in the Foxo-induced reduction of
ommatidia (p=0.1150, df=29) and area (p=0.2335, df=29) (Figure I).
Reduction in Pink] decreases the severity ofthe Foxo-induced phenotype
Overexpression of Foxo in a Pinkl mutant background (Pinkl B9) results in a significant
increase in ommatidia number (p=0.0008, df=21) and eye area (p=0.0015, df=21) (Figure
2). In addition, co-overexpression of Foxo with Pinkl RNAi shows an even greater effect,
with significant increases in ommatidia number and area (p<O.OOOl, df=30) (Figure 2).
These results suggest that the absence or depletion of Pink1 during eye development is
able to aIleviate the detrimental effects of Foxo. Overexpression of Foxo in a parkin
mutant background (parkin 45) or co-overexpression withparkinRNAi resulted in apparent
synthetic lethality with no surviving progeny. This implies that the broad protective
functions of parkin are necessary to maintain a viable organism during this development.
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Figure l. parkin increases the severity of the Foxo-induced phenotype. Co-overexpression ofFoxo with
parkin shows a significant reduction in number of ommatidia and overall area of the eye. Co-
overexpressionofFoxo with Pinkl shows no significant increase in the Foxo-inducedreductionof
ommatidia and area. Genotypes shown include GMR-Ga/4 UAS-Foxo/UAS-GFP (Foxo + GFP), GMR-
Ga/4 UAS-Foxo/+;UAS-Pinkl/+ (Foxo + Pinkl), GMR-Ga/4 UAS-Foxo/+;UAS-parkin/+ (Foxo + parkin).
Error bars indicate standard error of the mean.
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Figure 2. Reduction in Pinkl decreases the severity of the Foxo-induced phenotype. Overexpression of
Foxo in the Pinkl mutant background (Pinkl 89) results in a significant increase in ommatidia number and
eye area. Co-overexpression of Foxo with Pinkl RNAi (Pinkl RNAi) shows significant increases in
ommatidia number and area. Overexpression of Foxo in a parkin mutant background (GMR-Ga/4 UAS-
Foxo/+;parkin45/parkin45) or co-overexpression withparkinRNAi (GMR-Ga/4 UAS_Foxo/+;parkinRNAi/+)
resulted in apparent synthetic lethality. Genotypes shown include GMR-Ga/4 UAS-Foxo/UAS-GFP (Foxo
+ GFP), GMR-Ga/4 UAS-Foxo/+;UAS-PinkI RNAi/+ (Foxo + Pink) RNAi), PinkI89/y;GMR-Ga/4 UAS-
Foxo/+ (Foxo + Pink I 89). Error bars indicate standard error of the mean.
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Effects ofPink] and parkin on the Foxo-induced phenotype are independent of
Akt signalling
The constitutively active version ofFoxo (FOXOAA ) contains an alanine substitution at the
TI (T24A) and SI (S253A) Akt phosphorylation sites (Biggs et al. 1999). Using FOXOAA,
the severity of the Foxo-induced phenotype was seen to increase with Pinkl or parkin co-
overexpression (Figure 3). Co-overexpression of Pinkl with FOXOAA results in significant
decreases in number of ommatidia and eye area (p<O.OOO I, df=30). Co-overexpression of
parkin with FOXOAA also results in significant decreases in number of ommatidia
(p=0.0090, df=29) and eye area (p=O.O 190, df=29). The apparent rescue of the Foxo-
induced phenotype, seen when co-overexpressing Foxo with PinklRNAi(Figure 2), is
maintained when using the constitutively active version, FOXOAA (Figure 4). Co-
overexpression of FOXOAA with Pinkl RNAi results in a dramatic increase in ommatidia
number and eye area (p<0.000 I, df=30). These results indicate that the Pinkl/parkin
interaction with Foxo is independent of Akt signalling. In contrast, there is no significant
difference in ommatidia number (p=0.2131, df=29) or eye area (p=0.8027, df=29) when
FOXOAA is overexpressed in the Pinkl B9 mutant background (Figure 4). As seen with Foxo
overexpression, co-overexpression of FOXOAA with parkinRNAi resulted in apparent
synthetic lethality with no surviving progeny.
Discussion
Under cell stress conditions, Foxo transcription factors are activated, targeting genes that
promote cell cycle arrest, stress resistance, or apoptosis (Greer and Brunet 2005). The
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Figure 3. Effects ofPink! and parkin on the Foxo-induced phenotype, independent of Alet signalling. Co-
overexpression of FOXOAA (FoxoAA) with Pink! results in significant decreases in number of ommatidia and
eye area. Co-overexpression of FOXOAA with parkin results in significant decreases in number of ommatidia
and eye area. Genotypes shown include GMR-GaI4/UAS-GFP;UAS-FoxoAA/+ (FoxoAA + GFP), GMR-
Ga14/+; UAS-FoxoAA/UAS-Pink! (FoxoAA + Pinkl), GMR-GaI4/+; UAS-FoxoAA/UAS-parkin (FoxoAA +
parkin). Error bars indicate standard error of the mean.
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Figure 4. Effects of reductions in Pinkl on the Foxo-induced phenotype, independent of Akt signalling.
Co-overexpression of FOXOAA (FoxoAA) with Pinkl RNAi (Pink I RNAi) results in a dramatic increase in
ommatidia number and eye area. Overexpression of FOXOAA in the Pinkl mutant background (Pinkl 89) is
not significantly different from the control. Co-overexpression of FOXOAA with with parkinRNAi (GMR-
Gal4l+; UAS_FoxoAAlparkinRNAil+) resulted in apparent synthetic lethality. Genotypes shown include
GMR-GaI4IUAS-GFP;UAS-FoxoAAf+ (FoxoAA + GFP), GMR_GaI41+;UAS_FoxoAAIUAS_PinkIRNAi
(FoxoAA + Pinkl RNAi), PinkI 89Iy;GMR-GaI41+;UAS-FoxoAAI+ (FoxoAA + Pinkl 89). Error bars
indicate standard error of the mean.
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transactivation ofPink] by Foxo (Mei et aI. 2009; Sengupta et aI. 2011) suggests that
there may be recruitment of the Pinkl/parkin pathway to help maintain mitochondrial
homeostasis during these types of cell stress. As opposed to the general tagging of toxic
proteins for degradation, studies indicate that the Pinkl/parkin pathway confers cell
protection by regulating fission/fusion events, triggering mitophagy to degrade
dysfunctional mitochondrial fragments when they cannot be repaired (Chu 20 I0;
Jendrach et aI. 2009). Studies have shown that recruitment of parkin by Pinkl to
depolarized mitochondria results in the ubiquitination of mitochondrial proteins VDACI
(Geisler et aI. 2010) and mitofusin (Gegg et aI. 2010; Ziviani et aI. 2010), leading to
recruitment of autophagic proteins or decreasing mitochondrial fusion, thereby promoting
mitophagy. It is hypothesized that when this process is impaired, by mutations in either
Parkin or Pinkl, an accumulation of defective mitochondria results, leading to the
neurodegeneration seen in Parkinson disease (Vives-Bauza et aI. 2010). In contrast, our
results indicate that Pink I/parkin may be involved in aspects of cell fate other than
protection. Our findings show that co-overexpression of Pink] or parkin results in an
increased severity of the Foxo-induced phenotype, and that a reduction in Pink] is able to
improve the phenotype. This suggests that there may be a more complex role for the
Pinkl/parkin pathway under differing cell stress conditions.
Many transcriptional targets ofFoxo have been identified, including molecules involved
in metabolism, oxidative stress resistance, cell cycle arrest and apoptosis (van der Horst
and Burgering 2007). Previous phenotypic studies using the Drosophila eye have
identified the pro-apoptotic Hid gene as one responsible target, where overexpression of
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Hid causes dramatic eye degeneration (Kanao et al. 2010; Wilson et al. 2002). Hid
functions by inactivating lAPs (inhibitor of apoptosis proteins), which in tum results in
caspase activation and apoptosis. This is similar to the role of HtrA2/0mi and
Smac/DIABLO in humans. Other components of mitochondrial dependent apoptosis are
also functionally conserved between Drosophila and mammals (Igaki and Miura 2004).
These include homologues and functional orthologues to BCL-2 proteins, lAPs, Apaf,
AIF, EndoG, VDAC, caspases, and cytochrome c, among others. Interactions between
these homologues and Hid, or other Foxo targets, may explain the results observed in our
study. One possible link could be the involvement ofVDAC during mitofission events,
where recruitment of parkin to the mitochondrial membrane results in the ubiquitination
ofVDACI (Geisler et al. 2010). VDAC is a major component of the permeability
transition pore (PTP), and is involved with mitochondrial outer membrane
permeabilization (MOMP) through interactions with pro-apoptotic BcI-2 proteins Bax
and Bak (Green and Kroemer 2004). With both the permeability transition pore and
mitochondrial outer membrane permeabilization implicated as initiators of apoptosis,
mitofission events triggered by ubiquitination ofVDAC must be controlled so to prevent
release of apoptotic factors from the mitochondria. Compounding factors such as the
effects of Hid in the Foxo-induced phenotype, may result in overwhelming instability
during increases in Pink] or parkin expression, making this degree of control impossible.
In this instance, the Pinkl/parkin pathway may actively participate in the initiation of
apoptosis, whereas during other types of cell stress, they maintain their traditional
protective roles.
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Expression of the constitutively active version of Foxo (FOXOAA ) with co-overexpression
ofPinkl, parkin or Pinkl RNAi seems to indicate that the Pinkllparkin effect on the Foxo-
induced phenotype is independent of Akt signalling. In contrast, the change in
significance when expressing FOXOAA in the Pinkl B9 mutant background suggests that
there is Akt involvement. This may indicate that there is a role for Pinkl in the cell that is
independent of its kinase function, and that this additional role is somehow involved in
the Akt signalling pathway. In this respect, the apparent rescuing effect of the Foxo-
induced phenotype during decreases in Pinkl expression would be partially due to the
decrease in kinase activity, and partially due to the presence of the Pinkl protein. Future
studies looking into an additional role for PinkI, apart from its kinase function, may yield
new interactions and targets in the PinkIlparkin pathway.
In conclusion, our results suggest that Pink} and parkin are able to increase the effects of
Foxo in Drosophila, highlighting a role for both Pinkl and parkin in regulating cell death.
In addition, the constitutively active version ofFoxo allows us to exclude a general
requirement for Akt when increasing the expression ofPinkllparkin, however, suggests
that there may be an additional role for Pinkl apart from its kinase function, which
warrants further investigation. The possibility remains that other interactions between
proteins linked with the Pinkl/parkin and INR pathways, such as the interaction ofPTEN
with DJ-l (Kim et al. 2005; Kim et al. 2009) may be involved in some way. Further
studies into the role ofPinkl/parkin in mitochondrial fission/fusion events, and additional
mitochondrial targets for Pinkl/parkin, may uncover underlying mechanisms that mediate
the shift towards apoptosis. Moreover, it is likely that the Pinkl/parkin pathway is
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involved in various aspects of cell fate decisions, contrary to the view that Pink I and
parkin act exclusively as protective proteins.
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Supplementary Results
parkin increases the severity ofthe Foxo-induced phenotype at 29°C
Co-overexpression ofFoxo with parkin results in an increase in the severity of the Foxo-
induced phenotype (Figure 8 I), showing a significant reduction in number of ommatidia
(p=0.0005, df=32) and overall area of the eye (p<0.0001, df=32). Co-overexpression
with Pinkl does not significantly affect the number of ommatidia (p=0.0642, df=32) or
area (p=0.5958, df=32) (Figure 8 I). These results are in agreement with those observed
at 25°C.
Reduction in Pink] decreases the severity ofthe Foxo-induced phenotype at
Overexpression ofFoxo in a Pinkl mutant background (PinkI B9) results in a significant
increase in ommatidia number (p=0.0335, df=27) and eye area (p=0.0424, df=27) (Figure
8 I). In addition, co-overexpression of Foxo with Pinkl RNAi shows an even greater effect,
with significant increases in ommatidia number and area (p<0.0001, df=31) (Figure 81).
Overexpression ofFoxo in a parkin mutant background (parkin45) or co-overexpression
with parkinRNAi resulted in apparent synthetic lethality. These results are in agreement
with those observed at 25°C.
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Effects ofPink] and parkin on the Foxo-induced phenotype are independent of
Akt signalling
Co-overexpression of Pinkl with FOXOAA results in significant decreases in number of
ommatidia and eye area (p<O.OOO I, df= 18) (Figure S2). Co-overexpression ofparkin
with FOXOAA also results in significant decreases in number of ommatidia (p=0.0002,
df=25) and eye area (p<0.000 I, df=25). Co-overexpression of FOXOAA with Pinkl RNAi
results in an increase in ommatidia number (p<0.000 I, df=26) and eye area (p=0.0037,
df=26). No significant difference was observed in ommatidia number (p=o.ono, df=24)
or eye area (p=0.1684, df=25) when FOXOAA is overexpressed in the Pinkl B9 mutant
background (Figure S2). Co-overexpression of FOXOAA with parkinRNAi resulted in
apparent synthetic lethality. These results are in agreement with those observed at 25°C.
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FigureSl. The severity of the Foxo-induced phenotype is increased by parkin and decreasedwith
reductions in Pinkl. Co-overexpression of Foxo with parkin at 29°C shows a significant reduction in
number of ommatidia (A) and overall area of the eye (B). Co-overexpression of Foxo with Pinkl shows no
significant change in the Foxo-induced reduction of ommatidia and area (A,B). Overexpression of Foxo in
the Pinkl mutant background (Pinkl B9) results in a significant increase in ommatidia number and eye area
(C,D). Co-overexpression of Foxo with PinkIRNA; (Pinkl RNAi) shows significant increases in ommatidia
number and area (C,D). Overexpression of Foxo in a parkin mutant background (GMR-Ga/4 UAS-
Foxo/+;parkin45/parkin45) or co-overexpression withparkinRNA; (GMR-Ga/4 UAS-Foxo/+;parkinRNA;/+)
resulted in apparent synthetic lethality. Genotypes shown include GMR-Ga/4 UAS-Foxo/UAS-GFP (Foxo
+ GFP), GMR-Ga/4 UAS-Foxo/+;UAS-Pinkl/+ (Foxo + Pinkl), GMR-Ga/4 UAS-Foxo/+;UAS-parkin/+
(Foxo + parkin), GMR-Ga/4 UAS-Foxo/+;UAS-PinkI RNA;/+ (Foxo + Pinkl RNAi), PinkI 89/y;GMR-Ga/4
UAS-Foxo/+ (Foxo + Pinkl B9). Error bars indicate standard error of the mean.
103
Ac
.. 30
~
~ 20
'0
~ 10
B
D
Figure 82. Effects ofPinkl and parkin on the Foxo-induced phenotype, independent of Alet signalling.
Co-overexpression of FOXOAA (FoxoAA) with Pinkl results in significant decreases in number of ommatidia
and eye area (A,B). Co-overexpression of FOXOAA with parkin results in significant decreases in number of
ommatidia and eye area (A,B). Co-overexpression of FOXOAA (FoxoAA) with Pinkl RNA' (Pink) RNAi)
results in a dramatic increase in ommatidia number and eye area (C,D). Overexpression of FOXOAA in the
Pinkl mutant background (Pinkl B9) shows no significant change in the FOXOAA phenotype (C,D). Co-
overexpression of FOXOAA with withparkinRNA' (GMR-GaI41+; UAS_FoxoAAlparkinRNA'I+) resulted in
apparent synthetic lethality. Genotypes shown include GMR-GaI4IUAS-GFP;UAS-FoxoAAI+ (FoxoAA +
GFP), GMR-GaI41+; UAS-FoxoAAIUAS-Pinkl (FoxoAA + Pinkl), GMR-GaI41+; UAS-FoxoAAIUAS-parkin
(FoxoAA + parkin), GMR-Gal41+;UAS-FoxoAAIUAS-Pinkl RNA' (FoxoAA + Pinkl RNAi), Pinkl B9Iy;GMR-
Gal41+;UAS-FoxoAAI+ (FoxoAA + Pinkl B9). Error bars indicate standard error of the mean.
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Chapter 5
Pink] rescues Gal4-induced developmental
defects in the Drosophila eye
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Abstract
Parkinson disease pathology often includes the presence in the remaining neurons of
ubiquitin-positive, a-synuclein-enriched inclusions known as Lewy bodies. Pink] (PTEN
induced putative kinase i), identified as PARK6, encodes a serine-threonine kinase
involved in mitochondrial protection, that works with parkin to ubiquitinate various
proteins, promoting mitophagy and possibly tagging cystolic proteins for degradation.
Previous work in our laboratory has examined the adverse effects of expressing toxic
proteins, including Gal4, and has shown the ability ofparkin to rescue a Gal4-induced
phenotype. To further investigate the role of Pink1 in protection against the toxic effects
of proteins, we have performed expression studies to determine the effects of increases
and decreases of Pink1 on the Gal4-induced phenotype of developmental defects in the
Drosophila eye. Our results show that Pink] is able to rescue the Ga14-induced
phenotype, suggesting that Pink1 can protect against the effects of the Gal4 protein.
However, we have found that reductions in Pink] or parkin do not have harmful effects
and are not able to induce a phenotype when combined with low level Gal4 expression.
This suggests that the effects of low level Gal4 are independent of Pink] or parkin, or that
there is an alternative mechanism to alleviate the low level effects of Ga14. Our findings
highlight the protective role of Pink1 against toxic proteins, and suggests that further
investigation into the Pink I mechanism of action during differing types of cell stress is
warranted.
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Introduction
Parkinson disease (PD) is the most prevalent neurodegenerative movement disorder
(Weintraub et al. 2008). Characterized by a progressive loss of dopaminergic neurons,
PD pathology often includes the presence of Lewy bodies, ubiquitin-positive and u-
synuclein-enriched inclusions, in the remaining neurons. Although sporadic forms ofPD
are believed to be more common, many familial forms share features with sporadic PD,
including protein aggregation and mitochondrial dysfunction (Dawson and Dawson
2003). Pinkl (PTEN induced putative kinase l) encodes a serine-threonine kinase which
has been linked to autosomal recessive and some sporadic forms of Parkinson disease
(Jendrach et al. 2009; Valente et al. 2004a; Valente et al. 2004b). Targeted to the
mitochondria, Pink1 is involved in mitochondrial protection, as loss of function of Pink I
results in substantial mitochondrial defects in sensitive tissues (Clark et al. 2006; Exner et
al. 2007; Hoepken et al. 2007; Park et al. 2006; Yang et al. 2006). It is increasingly
apparent that both Pinkl and parkin, acting in the same pathway, are necessary for proper
mitochondrial integrity and function (Poole et al. 2008; Yang et al. 2008). The parkin E3
ubiquitin ligase acts downstream of Pink1. In mitochondrial protection, the recruitment
of parkin to the mitochondria by Pinkl results in the ubiquitination of various
mitochondrial proteins, promoting mitophagy (Gegg et al. 2010; Geisler et al. 2010;
Vives-Bauza et al. 2010; Ziviani et al. 2010). In addition, Pinkl may have a protective
role apart from the mitochondria, where an interaction with parkin could result in the
tagging of cystolic proteins for degradation. This may be an important, but largely
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overlooked role, as neurodegenerative diseases are often characterized by the
accumulation oftoxic proteins.
Our laboratory has examined the adverse effects of expressing proteins that can produce
toxicity, including a-synuclein and the Gal4 transcription factor (Haywood and Staveley
2004,2006; Haywood 2006; Kramer and Staveley 2003). We have shown the ability of
parkin and Pinkl to rescue an a-synuclein-induced phenotype (Haywood and Staveley
2004, 2006; Todd and Staveley 2008), and the ability ofparkin overexpression to rescue a
Gal4-induced phenotype (Haywood 2006). The suppression of the effects ofGal4 is
presumably through its targeting for proteosomal degradation by parkin. To further
investigate the role of Pink I in protection against toxic proteins, we have performed
expression studies to determine the effects of Pinkl on the Gal4-induced phenotype of
developmental defects in the Drosophila eye. Our results show that Pinkl is able to
rescue the Gal4-induced phenotype, suggesting that Pink I can protect against the effects
of the Ga!4 protein.
Materials and Methods
Fly stocks and culture
The VAS-Pinkl transgenic line was created from the GH2093I Drosophila melanogaster
Pink! clone (Todd and Staveley 2008). The Pinkl 89 mutant line (Park et al. 2006) was
provided by Dr. J. Chung. The VAS_Pinkl RNAi and VAS_parkin RNAi lines (Yang et al.
2006; Yang et aJ. 2003) were provided by Dr. B. Lu. VAS-parkin was created previously
in our laboratory (Haywood and Staveley 2004). The parkin45 mutant line (Greene et al.
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2003) was provided by Dr. L. Pallanck. The GMR-GaI4 flies (Freeman 1996) were
obtained from the Bloomington Drosophila Stock Center at Indiana University. All
crosses were performed using standard techniques. All flies were cultured on standard
cornmeallyeast/molasses/agar media.
Scanning electron microscopy ofthe Drosophila eye
Flies were aged three days past eciosion on standard cornmeallyeast/molasses/agar media
at either 25°C or 29°C. Flies were then frozen at -80°C and examined under dissecting
microscope. Flies were mounted, desiccated overnight and coated in gold before
photography at 170 times magnification with a Hitachi S-570 SEM. Area of disruption
was determined by the presence of fused or enlarged (> 150%) ommatidia.
Results
Pink] is able to rescue the Gal4-induced rough eye phenotype
High levels of Gal4 expression in the developing Drosophila eye result in a characteristic
rough eye phenotype (Kramer and Staveley 2003). At 25°C, GMR-GaI4 homozygotes
have a rough eye phenotype characterized by an 81 % ommatidial disruption of the eye
area (Figure I). Co-overexpression with one copy of the Pink] transgene results in a
significant reduction of the Gal4-induced phenotype, reducing the disruption to 5% (95%
CI). Co-overexpression with two copies of the Pink] transgene results in a further,
significant reduction of the Ga14-induced phenotype, near control levels (0.5% disruption,
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Figure 1. Pinkl decreases the severity of the Gal4-induced phenotype. GMR-GaI4 homozygotes show a
characteristic rough eye phenotype. Co-overexpressionwithoneortwocopiesofthePinkltransgene
results in a significant reduction of the Gal4-induced phenotype. Genotypes shown include willS (WII18),
GMR-GaI4/GMR-GaI4 (GaI4/GaI4), GMR-GaI4/GMR-GaI4; UAS-Pinkl/+ (GaI4/Ga14; Pink!), GMR-
GaI4/GMR-GaI4; UAS-Pinkl/UAS-Pinkl (Ga!4/Ga14; Pinkl/Pinkl). Flies were raised at 25°C. Error bars
indicate standard error of the mean.
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95% CI). These results suggest that an increase in Pinkl, in a dose dependent manner,
during eye development is able to alleviate the detrimental effects of Gal4 expression.
GMR-Ga14 heterozygotes show a mild rough eye phenotype at 29°C
Previous work in our laboratory indicates a mild Gal4-induced phenotype in GMR-GaI4
heterozygotes at 29°C, with intermediate levels of apoptosis (Kramer and Staveley 2003).
Our results with GMR-Ga14 heterozygotes at 29°C show this mild phenotype, with an
unevenness of the ommatidial surface, and no visible fusing of ommatidia or enlargement
greater than 150% (Figure 2). Due to the subtle nature ofthe phenotype, it is difficult to
determine if co-overexpression of either one or two copies of the Pinkl transgene has an
effect. Therefore, possible protective effects of Pinkl overexpression on the GMR-Ga14
heterozygotes cannot be detected using this phenotype.
Reductions in Pink] or parkin are not able to induce a rough eye phenotype in
GMR-Ga14 heterozygotes
It was of interest to determine if reductions in Pinkl or parkin have an effect on the subtle
phenotype observed in the GMR-Ga14 heterozygotes at 29°C (Kramer and Staveley
2003)(Figure 2). Our results show no appreciable change in eye morphology during co-
overexpression ofparkinRNAi, Pinkl RNAi or when GMR-GaI4 heterozygotes are expressed
in a Pinkl mutant background (Pinkl 89)(Figure 2). These results suggest that reductions
in Pinkl or parkin are not sufficient to induce the Ga14-induced phenotype. Expression
in a parkin mutant background resulted in apparent synthetic lethality (GMR-GaI4/+;
III
Figure 2. Reductions in Pinkl or parkin do not induce a rough eye phenotype in GMR-Ga/4 heterozygotes.
GMR-Ga/4 heterozygotes show a mild phenotype of unevenness in the ommatidial surface, with no visible
fusing of ommatidia or enlargement over 150% (red arrow). No changes were observed with co-
overexpression of Pinkl,parkinRNA'. Pinkl RNA' or when expressed in the PinklB9 mutant background.
Expression in a parkin mutant background resulted in apparent synthetic lethality (GMR-Ga/41+;
park'5Ipark'\ Genotypes shown include willS (WillS), GMR-Ga/41+ (GaI4/+), GMR-Ga/41+; UAS-
Pinkl/+ (GaI4/+; Pinkl), GMR-Ga/41+; UAS-Pinkl/UAS-Pinkl (GaI4/+; PinkllPinkl), GMR-Ga/41+;
UAS_parkinRNAil+ (GaI4/+;parkinRNAI), Pinkl B9ly; GMR-Ga/41+ (GaI4/+; Pink IB9), GMR-Ga/41+;
PinklRNAij+ (GaI4/+; PinkRNA;). Flies were raised at 29°C.
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pare5/park45). This implies that the broad protective functions of parkin are necessary to
maintain a viable organism during this development.
Discussion
Increase in Pink} expression during eye development is able to alleviate the detrimental
effects of Ga14 expression in a dose dependent manner. The ability ofPink} to
counteract the effects of GMR-GaI4 is similar to previous results in our laboratory with
parkin (Haywood 2006), supporting the theory that Pinkl is acting via parkin. Pinkl may
interact with parkin to activate the ubiquitin-proteasomal system, resulting in the tagging
ofGal4 for degradation. Alternatively, Pinkl may operate to protect the mitochondria
from the effects of Ga14, recruiting parkin to the membrane to remove damage via
mitophagy. Studies have shown that recruitment of parkin by Pinkl to depolarized
mitochondria results in the ubiquitination of mitochondrial proteins VDACI (Geisler et
al. 2010) and mitofusin (Gegg et al. 2010; Ziviani et al. 2010), leading to recruitment of
autophagic proteins or decreases in mitochondrial fusion. It is hypothesized that when
this process is impaired, by mutations in either parkin or Pink}, an accumulation of
defective mitochondria results, leading to the neurodegeneration seen in Parkinson
disease (Vives-Bauza et al. 2010). Pinkl may impart mitochondrial protection by
interacting with other molecular chaperones at the mitochondrial membrane. For
example, the phosphorylation ofTRAPI (Hsp75) by Pinkl has been shown to protect
against oxidative stress and prevent cytochrome c release (Pridgeon et al. 2007).
Identification of PINK I targets is still in early stages. It is likely that PINKI will be
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identified to interact with various proteins, and serve to protect against multiple stressors
such as toxic proteins, oxidative stress and mitochondrial dysfunction.
The GMR-Gal4 heterozygotes exhibit a mild phenotype at 29°C, with intermediate levels
of apoptosis in the eye imaginal discs (Kramer and Staveley 2003). It was thought that
this mild Ga14-induced effect may be increased with reductions in Pink] or parkin,
inducing a measurable rough eye phenotype. Our results show that these reductions are
not sufficient to induce a rough eye phenotype, implying that either the levels ofGal4 are
not enough to cause developmental defects, or that low levels ofPink] or parkin may be
sufficient to protect against low levels of Gal4. The lack of an effect observed using the
Pinkl B9 mutant may suggest that a functional kinase is not necessary for Pinkl to
participate in protection against the effects ofGal4. As interactions with the Foxo-
induced phenotype have suggested that Pink] may have a role independent of its kinase
function, investigations into other aspects ofthe Pink I protein may shed light on
unexplored roles or interactions.
In conclusion, our results show that Pink] is able to decrease the effects of Gal4 in
Drosophila, highlighting a protective role for PinkI against the effects oftoxic proteins.
Our results suggest that low levels of Pinkl or parkin may be sufficient to protect against
low levels of Gal4, and that a functional kinase may not be necessary for Pink I to
participate in this protection. It is likely that Pink! has a diverse role in cell protection,
including interaction with parkin in the ubiquitin-proteasomal system, regulation of
mitochondrial fission/fusion events, and other roles that may be independent of its kinase
1!4
function. Further investigation into the Pinkl mechanism of action will be important in
revealing different protective roles that are dependent upon the type of cell stress.
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Chapter 6
Discussion and Conclusions
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Pink] is able to alleviate the effects of toxic proteins
Aggregation and accumulation oftoxic proteins is a unifying feature of various
neurodegenerative disorders (Kopito and Ron 2000). The aggregation of a-synuclein is a
central pathogenic mechanism for Parkinson disease and has been linked to various
aspects of mitochondrial dysfunction (Lee and Trojanowski 2006; Schapira and Gegg
2011). The ability of Pink! to counteract the effects of a-synuclein are similar to those
observed with parkin (Haywood and Staveley 2004), supporting the theory that Pink I and
parkin act in a common pathway where Pinkl can act through parkin to confer a
protective role against toxic proteins. This is further supported by our results showing the
ability ofPink! to alleviate the detrimental effects of Gal4 expression in a dose dependent
manner. The exact mechanism of how Pinkl protection against toxic proteins occurs is
still unclear. Pinkl may activate parkin directly or indirectly, thereby activating the
ubiquitin-proteasomal system, resulting in the tagging of a-synuclein for degradation.
Alternatively, Pinkl may confer mitochondrial protection through the recruitment of
parkin to the mitochondrial membrane, leading to the eventual segregation and mitophagy
of damaged mitochondria (Chu 2010; Whitworth and Pallanck 2009). Pinkl could act
independently of parkin, through an interaction with molecular chaperones such as
TRAPI (Pridgeon et al. 2007), protecting the mitochondria from oxidative stress caused
by the presence of toxic proteins. Oxidative stress is another unifying characteristic of
neurodegenerative diseases, and is implicated in the pathogenesis of a-synuclein (Devi et
al. 2008; Liu et al. 2009). Oxidative stress in the a-synuclein model may also playa role
in initiating mitophagy, where the ROS produced can act as signalling molecules in the
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regulation of autophagy (Scherz-Shouval and Elazar 2007; Weber and Reichert 2010).
Our results suggest that increases in a-synuclein and Pink] together can have a synergistic
effect in a specific population of dopaminergic cells, allowing for enhanced protection
and increased functional longevity in Drosophila. This may be a result of the
upregulation of pro-survival mechanisms via Pink1, in response to an increase in ROS
signalling due to a-synuclein overexpression. Regardless of the mechanism, Pink] is able
to counteract the effects of toxic proteins resulting in cell protection and, in some cases,
increased survival of the organism. This role ofPink1 has been largely overlooked in the
research community and warrants further investigation.
Pink! is able to increase lifespan and healthspan
Late age onset is the most striking feature of human neurodegenerative disorders, with
age considered to be the largest risk factor for the development and progression of
Parkinson disease (Lees et al. 2009; Weintraub et al. 2008). Studies with various
neurodegenerative diseases have revealed mechanistic links between ageing and the onset
of toxic protein aggregation (Dillin and Cohen 2011). Additionally, increased lifespan in
some models has been attributed to either the reduction of protein aggregates, or the
protective aggregation of toxic cytoplasmic proteins. Our results suggest that combined
increases in a-synuclein and Pink] can have a synergistic effect of increased longevity,
but only in a specific population of dopaminergic cells targeted with the TH-GaI4 driver.
It is likely that the protective effects ofPink] on the a-synuclein phenotype are due to
downstream tagging of a-synuclein for destruction, and/or maintenance of overall
mitochondrial function in the cell through the mitophagy of damaged mitochondria.
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Interestingly, the increases in lifespan were not observed when using other neuronal and
ubiquitous drivers, and are not observed when using Ddc-Ga14 to drive expression in the
dopaminergic neurons. There is growing evidence that the TH-GaI4 and Ddc-Gal4
drivers have differing coverage ofthe dopaminergic neurons (Yarali and Gerber 2010).
Our results therefore suggest that a specific dopaminergic cell cluster, targeted by TH-
Gal4 but not by Ddc-GaI4, is responsible for the observed increases in longevity.
Identification of this neuronal population could shift future therapeutic efforts towards a
particular dopaminergic cluster.
Pinkl and parkin have complex roles in cell fate decisions
The Pinkl/parkin pathway is commonly viewed exclusively as a protective pathway. In
contrast, our results show that an increase in Pink] or parkin is able to increase the
damaging effects of the directed over-expression ofFoxo in Drosophila, highlighting a
role for the PinkI/parkin pathway in regulating cell death. This role may be dependent on
the type of cell stress, where Foxo transcription factors are often involved in nutritional
stress, targeting genes promoting cell cycle arrest, stress resistance, or apoptosis (Greer
and Brunet 2005). The transactivation ofPink] by Foxo (Mei et al. 2009; Sengupta et al.
2011) was assumed to promote stress resistance, via maintenance of mitochondrial
homeostasis. However, our results suggest that recruitment of the Pinkl/parkin pathway
may not always be a protective mechanism. It is possible that, under certain conditions,
Pinkl/parkin serve to initiate formation of the permeability transition pore (PTP) and/or
mitochondrial outer membrane permeabilization (MOMP). In this instance, Pinkl/parkin
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may actively participate in the initiation of apoptosis, whereas during other types of cell
stress, they maintain their traditional protective roles.
Our expression studies using Foxo suggest that there may be an additional role for Pinkl
apart from its kinase function. Using an RNAi approach to target Pinkl appears to
improve the Foxo phenotype, independent of Akt involvement. Using the Pinkl B9
mutant, containing a nonfunctional kinase, improves the Foxo phenotype to a lesser
degree, and appears to be dependent on Akt involvement. This discrepancy suggests that
there may be a second mechanism at work. JfPinkl is able to confer protection without a
functioning kinase, but it is dependent on phosphorylation ofFoxo by Akt, then this
protective role may still be fulfilled when using the Pinkl B9 mutant. This is an interesting
prospect and future studies looking into non-kinase functions for Pinkl may yield new
interactions and targets in the Pinkl/parkin pathway.
Final thoughts and future directions
It was the purpose of this thesis to use expression studies in a Drosophila model to
investigate the protective role ofPinkl and interactions it may have with other genes or
pathways. It has become clear that Pinkl plays a role in mitochondrial protection. Due to
the importance of mitochondria in maintaining cell sustenance, it is understandable that
mitochondrial dysfunction has detrimental effects in the cell. What is not so widely
known is the intricate signalling that occurs within, and exterior to, the mitochondria, that
can result in either its increased functionality, or in the initiation of apoptosis. The
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mitochondria act as major players in cell fate decisions, and the role of Pink1 with
mitochondria may be more complex than previously thought.
With the identification of PINK1 targets is in its infancy, it of interest to determine if
there are other PD related genes that Pink] is involved with. Five Pink I /parkin-
interacting genes have recently been identified in Drosophila (Fernandes and Rao 2011).
Further investigations into these and other gene interactions could be accomplished with
Drosophila expression studies, as many PD genes have homologues in Drosophila.
Alternatively, this model can also allow for relatively easy transgenic expression of genes
that have yet to have a Drosophila homologue identified. It is likely that PINKI is able to
interact with various proteins that mayor may not be linked to PD, proteins that serve to
protect against toxic proteins, membrane permeability, or oxidative stress. It is also
possible that proteins involved in apoptosis may interact with Pinkl, where studies
looking at the involvement of Pink I with Bcl-2 proteins would be of particular interest.
It is likely that Pinkl has a diverse role in cell fate decisions, including functioning in a
Pinkl/parkin pathway to operate in the ubiquitin-proteasomal system, regulate
mitochondrial fission/fusion events, regulate membrane permeability during apoptosis,
and other roles that may be independent of its kinase function. Further investigation into
the Pinkl mechanism of action will be important in revealing different protective roles
that may be dependent upon the type of cell stress.
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Appendix 1
Novel Assay and Analysis for Measuring
Climbing Ability in Drosophila
A version of this appendix has been published in Drosophila Information Services (Todd
and Staveley 2004)
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Introduction
The locomotor activity of Drosophila has been commonly used to investigate mobility in
ageing Drosophila and especially in Drosophila models ofneurodegenerative diseases
«Feany and Bender 2000; Haywood and Staveley 2004; Le Bourg and Lints 1992).
Climbing ability is a commonly used assay to measure locomotor activity. A frequently
applied method uses empty, standard size vials in which flies are evaluated as having the
ability to climb an eight centimetre distance or not. Our novel method employs a long,
thin tube in which flies are graded for various levels of climbing. Our approach to
analyze climbing is based upon an index that I) is sensitive to differences in climbing
ability and 2) uses non-linear fit curves that allow for easy comparison of data. The
following describes the assay design and analysis, along with a demonstration of how the
assay operates using data that was produced while investigating locomotor effects in a
Drosophila melanogaster model of Parkinson disease.
Materials and Methods
Drosophila Strains and Culture
The UAS-TH and UAS-Ddc (True et al. 1999) lines were generously provided by Dr. S.B.
Carroll (University of Wisconsin). The double Ddc-GAL4 driver line was generated by
standard genetic means from Ddc-GAL436 and Ddc_GAL443D (Li et al. 2000), provided by
Dr. J. Hirsh (University of Virginia). The WI/IS line was provided by Dr. H. Lipshitz
(University of Toronto). Individuals were generated for the assay by crossing WillS
females to males of the UAS-TH, UAS-Ddc and the double Ddc-GAL4 lines. All flies
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were raised upon standard cornmeal/yeast/molasses/agar medium at 25°C in standard
plastic shell vials.
Assay Design
The climbing apparatus (Figure I) consists ofa 30 cm long glass tube, with a diameter of
1.5 cm. The tube is held in place by a plastic funnel that acts as both a base for the tube
and as a means for transferring flies into the apparatus. Starting from the base, the glass
tube is divided into a series of five sections, each 2 cm in height (scored 1-5), with an
additional buffer zone in the upper portion of the apparatus. Sponges are placed in each
end of the tube to prevent escape yet allow air exchange.
Due to the natural negative geotaxis displayed by Drosophila, the flies climb up the sides
of the apparatus after being tapped down to the bottom. Flies are allowed ten seconds to
climb after being tapped down and are given a score based upon the sections reached.
The flies are scored ten times (trials) per climbing session, from which a climbing index
is calculated as follows:
Climbing index = ~(nm) / N
Where n = number of flies at a given level, m = the score for that level (1-5) and N = total
number of flies climbed for that trial.
For climbing analysis, fifty male progeny from each genotype under investigation are
collected within 24 hours of eclosion and separated into groups of ten individuals.
129
-+----- Sponge
t--t----- Glass tube
Buffer zone
Base
Figure 1: Schematic representation of the climbing apparatus. The apparatus consists ofa 30 cm long
glass tube, with a diameter of 1.5 cm. The tube is held in place by a plastic base that also actsasa funnel
for transferring flies into the apparatus. The glass tube is divided into five, 2 cmsections (1-5) with a buffer
zone at the top of the apparatus. The ends of the tube are plugged with sponges to prevent escape offlies.
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Starting at day one after eclosion, each group is tested for climbing ability and is
continually tested every five days throughout their lifespan.
Statistical Analysis
Data from the climbing assay was analyzed using the GraphPad Prism 4.02 program
(GraphPad Software Inc.). Climbing data were compared using curve fit comparison in
which the climbing index was subtracted from five and a non-linear regression curve fit
was performed. The resulting slopes of the fitted curves for each set of data were
compared with 95% confidence intervals.
The model generated for the climbing data using a non-linear regression curve fit is as
follows:
5- Climbing index = C eKt
Climbing index = 5- (C eKt)
Where C = constant, K= the slope of the fitted curve and t = time in days.
Results (Sample Analysis)
As a part of ongoing experiments looking at dopamine synthesis in relation to a model of
Parkinson disease, tyrosine hydroxylase (TH) and dopa-decarboxylase (Ddc) (True et al.
1999) were expressed using the UAS/GAL4 system for ectopic gene expression (Brand
and Perrimon 1993) and assayed for climbing ability. The climbing results from the
double Ddc-GAL4 flies and the UAS-TH and UAS-Ddc flies are presented (Figure 2). A
comparison of the UAS-THflies with the UAS-Ddc flies (Figure 2a) shows a small but
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Figure 2: Comparison of the climbing ability showing curves where a significant difference is present (a)
and where there is not a significant difference (b) The top graph ineach is the non-fitted data where the
bottom graph is the fitted curve. Error bars in the non-fitted graphs are standard error of the mean; most
error bars are within the area of the data point symbol.
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significant difference in climbing ability. The slopes for the fitted curves (Table I) are
0.056 and 0.046 respectively, and do not overlap within a 95% confidence interval (95%
CI). In contrast, comparison of the UAS- TH flies with the double Ddc-GAL4 flies (Figure
2b, Table 1) does not show a significant difference in climbing ability within a 95% CI
with slopes of 0.056 and 0.050 respectively.
Comparison to the Non-graded Method
A common method for analysis of climbing ability in Drosophila is a similar apparatus
with a single line at the 8 cm mark (Feany and Bender 2000; Haywood and Staveley
2004) in which flies are scored as being able or unable to reach the 8 cm distance. This
type of assay is usually performed in empty 9.5 x 2.7 cm vials. The 1.5 cm tube proposed
here presents less opportunity for individuals to fly in the apparatus. In addition, the non-
graded method results in less sensitivity when detecting differences in climbing ability.
Figure 3 shows a comparison of the graded method proposed here (Figure 3a) with the
non-graded method (Figure 3b) using the non-linear curve fit analysis for each. From
these graphs, it is apparent that the non-graded method is unable to detect climbing ability
when nearing the end oflifespan. In the non-graded method flies appear as unable to
climb when 70-80 days old, when they are actually able to climb between two and six
centimeters at this age, as shown in the graded method.
The non-graded method is also unable to discern the difference in climbing ability
between the UAS-TH flies and the double Ddc-GAL4 flies (Tables 2 and 3). In the graded
method (Table 2), the slope of the curve for the UAS-THflies has a 95% CI of 0.076-
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Table 1: Comparison of the non-linear fitted curves for climbing ability showing slopes (K), standard error
(SE), confidence intervals (CI), and generated models for each of the fitted curves.
Slope Standard error 95% Confidence Generated modelGenotype (K) (SE) intervals(CI) (Climbing index = 5_CeK')
w; P [UAS-TH; w+]J5In. /+
Climbing index =
0.052 to 0.059
5_(0.032eo,056t)
w;; P[UAS-Ddc; w+]125n J+
Climbing index =
0.046 0.0012
5-(0.087 eO 046')
w; P [Ddc-GAL4; w+]j(, /+ ; Climbing index =
0.0020 0.046 to 0.054
P [Ddc-GAL4; W+]4JD /+ 5-(0.053eo,050t)
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Figure 3: Comparison of graded (a) and non-graded (b) climbing methods using non-linear curve fit
analysis. The top graph in each is the non-fitted data where the bottom graph is the fi ttedcurve. Errorbars
in the non-fitted graphs are standard error of the mean; mosterrorbars are within the area of the data point
symbol.
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Table 2: Comparison of the non-linear fitted curves for climbing ability using the graded method showing
slopes(K),standarderror(SE),confidenceintervals(CI),andgeneratedmode1s for each of the fitted
Slope Standard 95% Confidence Generated modelGenotype (K) error (SE) intervals (CI) (Climbing index = 5_CeK1)
w;; P[UAS-TH; w+]'6012 /+
Climbing index-
0.080 0.0022 0.076 to 0.084
5_(O.014eo.0801)
w; P[UAS-Ddc; W+]'612 /+
Climbing index-
0.0024 0.054 to 0.063
5-(O.036eo.059t)
w; P [Ddc-GAL4; w+]''' /+ ; Climbing index =
0.065 0.0024 0.061 to 0.070
P [Ddc-GAL4; w+tJD /+ 5-(0.026 eO 0651)
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Table 3: Comparison of the non-linear fitted curves for climbing ability using the non-graded method
showing slopes (K), standard error (SE), confidence intervals (CI), and generated models for each of the
fitted curves.
Slope Standard 95% Confidence Generated modelGenotype (K) error (SE) intervals(CI) (Climbing index = 5_CeK1)
w;; P[UAS-TH; w+y6012 /+
Climbing index =
0.064 0.0019 0.060 to 0.068
5-(0.012eo,0641)
w; P[UAS-Ddc; W+]1612 /+
Climbing index =
0.050 0.0020 0.046 to 0.054
5-(0.023eOO5Ot)
w; P [Ddc-GAL4; w+]'o /+; Climbing index =
0.056 0.0021 0.052 to 0.060
P [Ddc-GAL4; W+]43D /+ 5_(0.016eo,0561)
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0.084, and does not overlap with the 95% CI for the double Ddc-GAL4 flies of 0.061-
0.070. In contrast, analysis of the same data using the non-graded method (Table 3)
results in overlapping confidence intervals for the slopes of the UAS-TH and the double
Ddc-GAL4 cohorts, with 95% Cl of 0.060-0.068 and 0.052-0.060 respectively.
Therefore, ifusing the non-graded method in this analysis, the difference in the climbing
ability between these two genotypes would not have been detected.
Discussion
Evaluation ofAssay
We propose that this novel, graded climbing assay is an accurate method for measuring
climbing ability in Drosophila. The narrow glass tube used in the climbing apparatus is
able to discourage Drosophila from flying upward within the tube, and therefore, the
index is a measure of climbing ability only. The narrow tube also helps to prevent flies
from falling long distances during the ten second climbing trial, making it easier to score
the highest point reached by each fly.
As early as by day twenty, and throughout the remainder of the assay, flies were
occasionally observed to move in horizontal circles in one graded section of the tube.
This usually occurred in the lowest section of the tube, and although these flies were very
mobile, their horizontal movement resulted in a low score and consequently a lower
climbing index for the genotype. Horizontal movement, as well as downward climbing
and complete lack of climbing, was often observed to increase as the trials progressed
from one through ten during a given session. These climbing behaviours contributed to
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the change in the slope of the fitted line with increasing trials as shown in Table 4.
However, it should also be noted that with each trial, the 95% Confidence Interval
decreases (Table 4) and indicates that with the addition of each trial the fitted slope of the
line becomes more accurate.
Conclusions
The climbing assay is an accurate measure of climbing ability in Drosophila. The novel
apparatus and longer testing period is more sensitive to differences as compared to the
commonly used non-graded method. The number of trials was determined to be
appropriate, however concerns remain about fatigue as a result of the continuous
repetition of the trials (with no break in between each trial). This is a problem in both the
proposed graded and non-graded methods and may be resolved by providing a controlled
break period between trials. Alternatively, a combination of a decrease in the number of
trials and an increase in the overall number oftlies tested may reduce the possibility of
fatigue. In summary, the combination of our novel apparatus and analysis provides an
accurate assay for climbing ability in Drosophila.
139
Table 4: The effect of number of trials performed during the climbing assay on the resulting slope (K) of
thenon-linearfittedlineandtheconfidenceintervalforclimbingability.
Genotype
Trial
w; P [Ddc-GAL4; w+]JO /+;
#
w;; P[UAS-TH; W+]'60f2 /+ w; P[UAS-Ddc; W+]16f2 /+
P [Ddc-GAL4; w+tJD /+
K=0.10±0.022 K=0.073±0.015 K=0.073±0.025
K=0.076±0.0087
K=0.075 ± 0.0070 K=0.077±0.011
K=0.075 ± 0.0091
K=0.073±0.0074
K=0.090±0.0055 K=0.066±0.0062
K=0.087±0.0051 K=0.071 ±0.0060
K=0.083 ± 0.0049 K=0.069±0.0053
K=0.082 ± 0.0045 K=0.061 ±0.0050 K=0.067±0.0050
10 K=0.080±0.0042 K=0.059 ± 0.0046 K=0.065 ± 0.0046
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Appendix 2
Co-expression of a-synuclein does not affect the reduction of
lifespan resulting from overexpression ofphosphatidylinositol
3-0H-kinase (P/3K) in Drosophila dopaminergic neurons
A version ofthis appendix has been published in Drosophila Information Services (Todd
and Staveley 2010)
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Introduction
The phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway is a ubiquitous and
evolutionarily conserved signalling cascade that functions in cell growth, survival,
proliferation, migration and metabolism (Endersby and Baker 2008). PI3K is a lipid
kinase that phosphorylates the three position of the inositol ring of phosphatidylinositoIs
and phosphoinositides (Engelman et al. 2006). A major downstream target ofPI3K
signalling is the serine-threonine kinase AKT, which, once activated, results in an anti-
apoptotic or cell survival signal. Cell culture experiments have demonstrated the rescue
of a-synuclein toxicity with activation ofthe PI3K pathway (Kao 2009), suggesting that
activation of this pathway may have broad protective effects.
In Drosophila melanogaster, as in mammals, PI3K plays a role in the conserved insulin
signalling pathway, regulating metabolism, growth and lifespan (Oldham and Hafen
2003). This pathway is negatively regulated by a PTEN orthologue. Previous
experiments show that deletion ofPI3K in Drosophila results in a reduction in cell size
and cell number, whereas deletion of PTEN leads to an increase in cell size and organ size
(Engelman et al. 2006). In contrast, we have previously shown an unexpected reduction
in lifespan with overexpression of PI3K in the dopaminergic neurons of Drosophila
(Saunders et al. 2003). Although unexpected, other studies have shown apoptosis with
overexpression ofPI3K (Klippel et al. 1998; Vanhaesebroeck et al. 2001). This suggests
a sensitivity in specific cell types may exist, likely sensitivity to the deregulation of the
cell cycle.
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Given the conflicting role of PI3K in the survival of doparninergic neurons, we looked at
the reproducibility of, and the possible effect that an additional stressor, in the fonn of a-
synuclein overexpression, may have on the reduced lifespan previously observed.
Materials and Methods
Fly stocks and culture
Dr. M. Feany (Harvard Medical School) generously provided UAS-a-synuclein flies
(Feany and Bender 2000), Dr. 1. Hirsh (University of Virginia) the Ddc-Gal4 flies (Li et
al. 2000), Dr. Sally Leevers (Ludwig College, London) the UAS-Pl3K-dpllO (PI3!C) and
UAS_PI3K_dplloD954A (PI3KDN) flies (Leevers et al. 1996), and the w///8 Iine was
provided by Dr. H. Lipshitz (University of Toronto). All flies were raised upon standard
commeallyeast/molasses/agar medium at 25°C in standard plastic shell vials.
Ageing assay
Approximately 300 adult males of each genotype were collected under gaseous carbon
dioxide and aged upon standard commeallyeast/molasses/agar media, at 25°C, in upright
standard plastic shell vials. Flies were maintained in non-crowded conditions with one to
twenty individuals per vial. Flies were scored for viability every two days and transferred
to fresh media according to established protocol (Staveley et al. 1990). Log-rank
(Mantel-Cox) test and Gehan-Breslow-Wilcoxon test were used to compare resulting
survival curves.
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Results and Discussion
Overexpression ofPJ3K using the Ddc-Ga14 tissue specific driver showed a dramatic
reduction oflifespan, with a median survival of 46 days as compared to 80 days seen in
the control (Log-rank and Wilcoson: p<O.OOOI) (Figure I). In contrast, expression of the
P13KDN showed a normal life span, median survival of78 days, as compared to the
control (Wilcoson: p=0.4495). As mentioned previously, these results are in contrast to
the typical role of the PI3K signalling pathway, as an initiator of cell growth and
proliferation. This is likely due to sensitivity in the dopaminergic cells with respect to
deregulation of cell cycle controls. In post-mitotic cells, including those in Drosophila,
PI3K signalling has been shown to control cell growth (cell size) as opposed to
proliferation (Engelman et a!. 2006). Cells may be triggered to undergo apoptosis due to
failure to progress through cycle (Klippel et a!. 1998; Vanhaesebroeck et a!. 2001). It
also appears that Drosophila lifespan is limited by metabolic activity and oxidative
damage to the nervous system in particular, opposed to other tissues (Shmookler Reis et
a!. 2009). Therefore, targeting of PJ3K expression to these sensitive cells may show an
effect that is otherwise unnoticed during expression in other tissues.
The PI3K pathway involves many levels of regulation including various negative
feedback mechanisms (Reviewed in Engelman et a!. 2006). In addition, activation of
downstream transcription factors can have various effects including the activation of
protective proteins such as PTEN induced punitive kinase I (Pink I) (Mei et a!. 2009).
Pink] has been shown to rescue an a-synuc/ein induced phenotype in Drosophila (Todd
and Staveley 2008), presumably through downstream tagging and degradation of u-
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synuclein. It was not found that this additional cell stressor of a-synuclein
overexpression contributes to the PI3K induced reduction in longevity. Overexpression
of a-synuclein with PJ3KDN using the Ddc-Gal4 tissue specific driver does not have a
substantial effect on lifespan, median survival 70 days, as compared to overexpression of
P13KDN alone, median survival 78 days (Log-rank: p=0.0677)(Figure I). Overexpression
of a-synuclein with P13K+ shows a slight increase in lifespan, median survival 52 days,
compared to overexpression of P13K alone, median survival 46 days (Log-rank and
Wilcoson: p<O.OOOI). This however is not rescued to the level of the a-synuclein or Ddc-
Gal4 controls (Log-rank and Wilcoson: p<O.OOOI). The engagement of protective
proteins such as Pink1 during a-synuclein cytotoxicity may not have enough of an effect
to increase the PI3K phenotype, alternatively, the detrimental effects of PJ3K may be too
severe on its own, or is initiated before a-synuclein induced cytotoxicity takes effect.
In conclusion, it appears that, in dopominergic neurons, overexpression of P13K results
in a severe decrease in lifespan, likely due to the sensitivity ofthis particular cell type
coupled with the inability ofthese cells to progress through cell cycle, thereby triggering
apoptosis. A substantial difference was not observed with the addition of a-synuclein
overexpression, and therefore, no conclusion can be made regarding possible links
between the PI3K signalling pathway and a-synuclein cytotoxicity.
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Appendix 3
Eyer: Automated Counting of Ommatidia using
Image Processing Techniques
A version of this appendix has been published in Drosophila Information Services
(Woodman et al. 201 I)
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Introduction
The UAS/GAL4 ectopic expression system (Brand and Perrimon 1993) is a widely used
tool for the overexpression of transgenes in Drosophila melanogaster. This bipartite
expression system allows for the expression of transgenes in specific tissues, including
the Drosophila eye using the glass multiple reporter (GMR)-GAL4 driver line (Freeman
1996). During this expression, it is of interest to measure differences in morphological
characteristics such as ommatidia number, ommatidial area and overall area ofthe eye.
This measurement is both time consuming and labour intensive given the number of
Drosophila required for analysis and the limitations of currently available programs.
Here, we describe a novel program designed for simple, morphological analysis such as
counting and area measurements. Although initially designed for analysis of the
Drosophila eye, this program could be used for analysis of various tissues, and could be
used for other applications apart from expression studies.
Design of Program
Software
The Eyer software was developed as the user interface for a segmentation algorithm
optimized for the Drosophila eye. It was written for the Windows platform using Visual
Studio C# and WPF. The image processing routines used by Eyer are performed by the
AForge.NET open-source imaging library and the Vincent-Soille immersion watershed
algorithm. The program was developed using images at a resolution of 1.33 pixels per
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micrometer. This equates to ommatidia that are approximately 20 pixels in diameter at the
center of the eye in adult Drosophila.
User interface
The Eyer software is a single purpose application, which allows for a completely tailored
interface to make the eye analysis task as quick and easy as possible. Instead of opening
individual image files, a folder is selected for editing, and all images are shown as a list of
thumbnails. The user can switch between active images by clicking on its thumbnail. An
image can be easily panned and zoomed via mouse or keyboard. All measurements
carried out on an image are automatically recorded in an associated text file and stored
with the image in the original folder.
Algorithm
There are several challenges presented to standard segmentation algorithms by the images
of Drosophila eyes. The convex nature of the eye results in ommatidia size and shape
variations across the eye leading to partially obscured ommatidia around the edge. The
lighting used when taking SEM images can vary over the surface of the eye and also from
image to image. Light spots and shadows cause the intensity of an ommatidium to be
unpredictable. The bristles that grow between Drosophila ommatidia reflect intense light,
creating further challenge for a segmentation algorithm. These bristles, from an image
processing perspective, appear to split many ofthe ommatidia while following along the
edge of others. For these reasons, the goal set for the development of the segmentation
algorithm was not to completely segment the eye, but to segment the largest area possible
153
with the highest accuracy. The portion of the eye not segmented by the software is then
completed manually.
The solution to the segmentation problem described above required a set of processes that
remove color variation and highlight the ommatidia edges uniformly. Once that had been
accomplished, an immersion watershed algorithm was used to separate and mark each
ommatidium. The complete algorithm can be described in five steps. (l) Contrast
Enhancement: This is achieved with a combination of histogram equalization, and
contrast stretching. (2) Edge Detection: Both horizontal and vertical edges are detected
with a standard edge detection routine. The edge detection results are added to the
contrast-improved image to further distinguish the lines around the ommatidia from the
centers. (3) Local Thresholding: Removal of all color intensity to create a black and white
image. The typical conversion method uses a threshold value, where intensities above that
value are white, and below are black. Since the intensity of the ommatidia varies over the
surface of the eye, an adaptive local threshold has to be used, where the value of the
threshold changes for each pixel, dependent on the surrounding area. After this step most
edges are visible, however many ommatidia still appear joined. (4) Watershed: The
watershed algorithm is able to separate connected blobs. This step processes the image as
ifit is a topographic relief, identifying locations where water would pool if poured onto
the image. (5) Blob Analysis: The resulting watershed lines are then used to segment the
eye. The list of segmented objects is filtered by size and shape by a blob analysis package
to determine which objects are valid ommatidia.
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Sample Analysis and Discussion
Drosophila
Flies of various genotypes were aged 3 days past eclosion and frozen at -80°C. Flies
were mounted, desiccated overnight, and coated in gold before photography at ISO times
magnification with a Hitachi S-570 scanning electron microscope as per standard
methods.
Area
To measure area, or to segment and image for counting purposes, the region of interest
(ROI) must be defined by the user. The ROI tool creates a point based polygon where
points can be easily added and removed while defining the area. The polygon can be
made with as many points as needed, resulting in a clearly defined area without the labour
intensive process of using a freehand tool. The total area of the eye is calculated in real
time and recorded in the associated text file as mentioned.
ISS
Figure 1: Original 1mare with User Defined HOI
Counting
The resolution of the image affects the performance and speed of the segmentation
required for counting. Higher resolutions will result in a higher segmentation percentage,
with a reduction in speed.
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The contrast enhancement performed by Eyer can be applied to the entire image
separately to improve the visibility of detail on the subject. This was found to be useful
when examining features such as the overall area of the eye.
After the segmentation process, identified ommatidia are marked with red dots. In this
example, segmentation took 4.8 seconds to complete, and it completed with 561 of 688
ommatidia correctly marked. 4 dots were placed incorrectly. The 4 false positives and
remaining unmarked ommatidia can be completed manually before the results are saved.
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Figure 3: Identified Ommatidia Marked by Eyer
Conclusions
Morphological analysis in Drosophila is widely used during expression studies to
investigate gene and protein function. In the Drosophila eye, measurement of
characteristics such as ommatidia number, ommatidial area and area of the eye are often
time consuming and labour intensive. Our novel program, Eyer, has been shown to be a
valuable tool for simple morphological analysis of the Drosophila eye. This program
could reduce the time needed for morphological analysis of various Drosophila tissues, as
well as tissues in other organisms.
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